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1 Introduction 
1.1 Reactive Oxygen Species 
For many years, reactive oxygen species (ROS) were viewed as detrimental and as undesirable due to 
their capacity to cause significant harm when their levels are too high, a condition termed oxidative 
stress. Since these readily reactive molecules, including superoxide anion (O2
-•), hydrogen peroxide 
(H2O2), hydroxyl radicals (HO•) and peroxynitrite anions (ONOO
-), were initially only regarded as an 
exhaust of cellular energy production, ROS were quickly categorised as harmful: they were shown to 
deactivate proteins, cause damage to DNA and ultimately lead to cellular apoptosis. Furthermore, 
levels of ROS were found to positively correlate with processes of aging as well as with a wide array 
of diseases, ranging from diabetes and cancer to neurodegeneration and cardiovascular pathologies.  
It is therefore not surprising that a great deal of effort has been invested in understanding how ROS 
are produced and how to decrease oxidative stress. As research progressed, it became apparent that 
the role of reactive oxygen species went beyond solely being a nuisance. Rather, elucidation of the 
cellular machinery which maintains ROS within a narrow range of concentrations enabled 
researchers to understand that ROS participate in vital cellular processes such as signalling, and 
regulation of transcription factors and proper protein function. 
1.1.1 Regulation of Reactive Oxygen Species 
For these reasons, it is essential for a cell to tightly control intracellular levels of ROS. In order to 
avoid excessive concentrations of ROS, endogenous or nutritional antioxidants such as glutathione, 
cysteine, uric acid, coenzyme Q, ascorbic acid (vitamin C), -tocopherol (vitamin E) or carotenoids 
are commonly available. Furthermore, cells are equipped with a range of highly efficient antioxidant 
enzymes, including superoxide dismutases (SOD), catalases, peroxiredoxins (Prx), the glutathione 
peroxidases and glutathione reductase, and the thioredoxin systems. The latter family of enzymes, 
together with glutathione, are now considered the major regulators of cellular redox states 1. 
Dysfunctionality or lack of any of these antioxidants can lead to detrimental effects associated with 
oxidative stress. 
 
1.2 Mammalian Thioredoxin System 
In mammals, enzymes belonging to the Thioredoxin family have been identified at distinct cellular 
locations. The most extensively researched enzymes, the oxidoreductases thioredoxin 1 (Txn1) and 
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thioredoxin reductase 1 (Txnrd1) are predominately present in the cytosol while the mitochondrial 
equivalents, thioredoxin 2 (Txn2) and thioredoxin reductase 2 (Txnrd2), have only recently gained 
attention. Cytosolic and mitochondrial thioredoxin systems have much in common; their main 
activity is focussed on maintaining proteins in a reduced state. An additional member of the 
thioredoxin family – TGR – was identified in the testes and its function differs from the 
cytosolic/mitochondrial equivalents in regard to its substrates, as TGR can reduce both thioredoxins 
and glutathione 2. 
1.2.1 Thioredoxins 
Irrespective of their site of expression, thioredoxins share a conserved -Cys-Gly-Pro-Cys- active site, 
enabling them to function as disulfide oxidoreductases 3. Initially, Txn was described as a hydrogen 
donor for ribonucleotide reductase, thus affecting DNA synthesis 4. Today, it is well established that 
thioredoxins participate in a much wider context of cellular redox regulation by reversible oxidation 
and reduction of the cysteine residues in their active site and are now considered the major protein 
disulfide reductase in a cell 3. In their reduced state (Txn-(SH)2), Txns can reduce disulfide bonds in 
proteins, thereby taking the oxidative burden upon themselves (Txn-S2). A lack of either Txn has been 
described to be embryonically lethal, thus emphasizing their vital importance 5, 6. This apparent 
importance is further manifested by the now well established plethora of roles of Txn.  
Thus, it has been shown that the cytosolic thioredoxin 1 (Txn1) can affect DNA transcription, for 
example by inducing NFκB transcriptional activity via reduction of a disulfide bond in the  
p50 subunit 7. However, the opposite effect on NFκB transcriptional activity has also been reported 8. 
These authors suggest that the activity-enhancing effect on NFκB is possibly due to Txn1 affecting the 
DNA-binding capacity of the transcription factor, whereas the inhibitory effect is due to Txn1 
preventing the liberation of NFκB from its inhibitor, IκB. Txn1 can also affect the transcriptional 
activity of the glucocorticoid receptor by directly affecting the receptor’s DNA binding domain and by 
stabilising the steroid-binding conformation of the ligand-binding domain 9, 10.  
Txn1 can also exert growth-promoting effects and as such has been shown to increase the 
proliferation of a range of solid tumour lines, possibly by increasing the susceptibility of receptors for 
autocrine growth factors 11. In line with this finding, Txn1 has been shown to be upregulated in a 
number of human cancers and also to inhibit drug-induced apoptosis in a manner requiring 
functional redox activity 12, 13.  
In contrast to the disadvantages on tumour progression, beneficial effects of Txn1 in the 
cardiovascular system have been reported. Thus, increased levels of Txn1 have been shown to 
prevent cardiac hypertrophy and to adapt transgenic mouse hearts to ischemia as well as protect 
from subsequent reperfusion injury 14,15. In line with these findings, the endogenous inhibitor of 
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Txn1, Thioredoxin-interacting protein (TXNIP), has been implicated in a range of cardiovascular 
diseases 16. In this study, the authors showed that physiological fluid shear stress decreases TXNIP, 
resulting in effective Txn1 reductive capacity and protection from vascular inflammation and 
subsequent initiation of atherosclerosis. In a follow-up study, the authors also showed that the 
opposite holds true: increased TXNIP-dependent inhibition of Txn1 occurs at atheroprone sites 
exposed to disturbed flow 17.  
Less is known on the protective or harmful effects of the mitochondrial equivalent of Txn1, Txn2. 
Since mitochondria are required for energy production and can also regulate critical cellular events, 
such as progression to cell death, the maintenance of homeostatic levels of ROS in mitochondria is 
vital. Damdimopoulos and colleagues demonstrated that Txn2 can modulate the response to the 
mitochondria-targeting cytotoxic compounds etoposide and rotenone, and that Txn2 is beneficial in 
the maintenance of a suitable mitochondrial membrane potential (ΔΨm) 18.  
In the cardiovascular system, overexpression of Txn2 has been shown to improve vasodilatory 
capacity, and to blunt blood pressure increases and reduce ROS production in response to chronic 
Angiotensin II infusion 19. Interestingly, in this study the authors describe that the decrease in ROS 
production was not limited to mitochondrial sources: overexpression of Txn2 also attenuated the 
usual Angiotensin II-induced increases in NADPH oxidase subunit expression, thus altering the 
production of ROS in the cytosol and implying a cross-talk between mitochondria and NADPH 
oxidase-dependent ROS production. Furthermore, in mice Txn2 is downregulated in ECs during hind-
limb ischemia and this occurs in parallel to increased ROS, leukocyte infiltration, activation of the 
transcription factor apoptosis signal-regulating kinase 1 (ASK1), and induction of apoptosis 20. 
Endothelial-specific overexpression of Txn2, on the other hand, improved recovery, thereby 
demonstrating a vital role of this mitochondrial antioxidant in vascular remodelling 20.  
1.2.2 Thioredoxin Reductases  
In order for either Txn to regain their reducing capacity, they themselves must be reduced by their 
respective reductases. This occurs in a NADPH-dependent manner, as depicted in Figure 1-1. Txnrds 
are selenoproteins that must form homodimers to exert their reducing effects 21. Txnrds consist of 
three domains: a NADPH domain, a flavin adenine dinucleotide (FAD) domain which receives 
reducing equivalents from NADPH, and an interface domain linking the two dimer subunits 22. In 
addition to the N-terminal active site which receives electrons from NADPH, the C-terminus includes 
a selenocysteine (Sec) residue at its active site (-Gly-Cys-Sec-Gly-), thereby producing a reversible 
selenenylsulfide/selenolthiol 23. Once the C-terminal selenolthiol motif has been formed, mammalian 
Txnrd can exert its reductive capacity upon a much wider range of substrates as is the case for Txnrds 
of bacteria or plants 23. Apart from their main substrate Txn, Txnrds can also reduce glutaredoxin 2, 
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the endoplasmic reticulum calcium-binding proteins CaBP1 and CaBP2 and protein disulfide 
isomerase 23-25. Furthermore, Txnrds can modulate the cytolytic activity of the antibacterial peptide 
granulysin, and Txnrd1 has been shown to reduce the glucose-responsive protein  
Thioredoxin-like 1 23, 26, 27. All these proteins share a certain sequence homology to Txn; a certain 
degree of diffusion of substrate specificity is thus not surprising. In addition to these aforementioned 
proteins, Txnrds have also been reported to directly reduce certain non-proteins substrates, such as 
selenium-containing compounds, dehydroascorbate (resulting in the reconstitution of ascorbate), 
cytochrome c and ubiquinone (Coenzyme Q10) 23, 28-30. In the case of the latter two compounds, both 
constituents of the electron transport chain (ETS), Txnrds possibly play vital roles in mitochondrial 
health and could therefore also impact on the mitochondrial contribution to the progression to 
apoptosis. The wide range of substrates that can be reduced by Txnrds is possibly due to its two 
active sites, the N-terminal FAD motif and the C-terminal Sec-containing sequence, which can both 
accept substrates, further exemplifying the importance of these enzymes in the maintenance of 
cellular integrity. 
 
Figure 1-1: General outline of thioredoxin system functionality. NADPH functions as electron donor to 
FAD which passes the electrons to the N-terminal redox active site of one Txnrd subunit. Subsequently, 
electrons are transferred to the C-terminal Gly–Cys–Sec–Gly active site of the other Txnrd subunit. Finally, 
oxidised Txn (Txn-S2) is reduced by the second Txnrd subunit. Reduced Txn (Txn-(SH)2) can then in turn reduce 
disulfide bonds in proteins. Image adapted from Holmgren & Lu 2010 
3
. 
 
It is therefore not surprising that systems lacking these enzymes or expressing only dysfunctional 
Txnrds are implicated in several pathological conditions. However, due to their considerable 
catalogue of substrates, it is difficult to differentiate between a direct influence of Txnrds and the 
oxidative defect of one of the substrates. A simplified view would be to expect that dysfunctional 
Txnrd leads to effects mirroring those of a lack of a certain substrate’s activity. For example, the 
phenotype of mice lacking Txnrd1 would be identical to that of mice lacking Txn1. This, however, is 
not the case. While Txn1-deficient embryos die at the time of implantation (embryonic day 6.5) and 
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the inner cell mass fails to proliferate in vitro 5, mice lacking Txnrd1 on the other hand survive until 
embryonic day 10.5, albeit with growth retardation and developmental abnormalities in a variety of 
organs 31. Thus, considering individual Txnrds as simple hydrogen donors for a limited number of 
substrates is insufficient when attempting to understand the precise role of these enzymes. 
The downside of the functional antioxidative activity of Txnrds, regardless of substrate-dependent or 
independent effects, is however, that these reductases have been reported to be upregulated in a 
number of cancers. In support of this notion, Txnrd1 deletion in Lewis Lung Carcinoma cells not only 
retarded tumour growth, these cells rather resembled normal cells 32. This finding is not surprising, 
considering that tumours grow in an environment of constant hypoxia, which is a stimulus for the 
production of ROS, a concept which will be discussed in more detail below 33. Txnrd1 could thus 
favour tumour growth by decreasing the oxidative burden and for this reason Txnrd1 is being 
considered as a target for the treatment of cancer. In recent years, however, it has become evident 
that, at least for Txnrd1, the involvement of Txnrd1 in cancer progression is more complex than 
initially anticipated. Indeed, a recent study demonstrated a protective effect of Txnrd1 on chemically-
induced liver cancer 34.   
In comparison to the involvement of Txnrd1 in cancer, reports on this enzyme’s function in the 
vascular compartment are limited. Pharmacological inhibition of Txnrd1 has been reported to 
attenuate the endothelium-dependent vasodilatory capacity of isolated mouse aorta in response to 
acetylcholine 35. The authors suggested that this was due to the lack of the antioxidant effects of 
Txnrd1, leading to inactivation of nitric oxide (NO) as well as its ability to reverse protein S-
nitrosylation. Of course, via its reducing capability, Txnrd1 may affect processes in the vasculature 
requiring functional activity of its array of substrates.  
1.2.3 Mitochondrial Thioredoxin Reductase 
Txnrd2 shows a high degree of sequence homology to Txnrd1 (84% for human Txnrd1 and Txnrd2), 
with the exception of an N-terminal extension on Txnrd2. This extension has been identified as a 
mitochondrial import sequence 36. The similarity between the two enzymes is exemplified in  
Figure 1-2. 
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Figure 1-2: Domain structures of the human cytosolic and mitochondrial thioredoxin reductases. 
Triangles indicate the catalytic active sites of the reductases. Adapted from Mustacich et al., 2000 
36
. 
 
In comparison to Txnrd1, investigation of the role of Txnrd2 is less advanced. A recent study in our 
laboratory showed that a lack of Txnrd2 in mouse embryonic fibroblasts (MEFs) transfected with the 
pro-oncogenes c-myc and Ha-ras resulted in significantly smaller tumour volume when implanted 
subcutaneously in C57BL/6 mice. Tumour proliferation was impaired due to poor neovascularisation 
and a failure to stabilise HIF-1α 37. In the cardiovascular system, Txnrd2 was shown to be 
indispensable for correct heart development as mice lacking Txnrd2 specifically in cardiomyocytes 
die shortly after birth due to dilated cardiomyopathy 38. In a follow up study in inducible 
cardiomyocyte-specific Txnrd2 knockout mice, cardiac ischemia/reperfusion injury led to 
mitochondrial swelling, and increased cardiomyocyte death, functional impairment and larger infarct 
size relative to wildtype counterparts 39. Resembling these findings, non-functional Txnrd2 with 
mutations in the highly conserved FAD domain have been shown to be present in some human 
patients with dilated cardiomyopathy, a form of congestive heart failure 40. The importance of Txnrd2 
in the heart is also revealed in embryos with a ubiquitous deletion of the enzyme. These embryos die 
prenatally (gestational day 13) and present profound defects in heart development and function. 
Furthermore, embryos with a ubiquitous lack of Txnrd2 suffer from significant impairments in 
haematopoiesis as well as severe anaemia and growth retardation compared to their wildtype or 
heterozygous counterparts 6, 38. Thus, like its cytosolic counterpart, Txnrd2 is indispensable for 
normal development. Interestingly, the defects observed in mouse embryos with ubiquitous deletion 
of Txnrd2 do not resemble those in Txn2-deficient mouse embryos. A lack of Txn2 results in massive 
apoptosis, an open anterior neural tube, and ultimately lethality at gestational day 10.5, which 
coincides with the time point of mitochondrial maturation and the initiation of oxidative 
phosphorylation. Possibly, the maintenance of mitochondrial functionality beyond E10.5 is 
N-terminal C-terminal 
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compensated by other enzymes, such as Txnrd1 or by GSH-dependent redox activity 38. In addition, 
the oxidative stress burden could also be relieved by other enzymes, e.g. mitochondrial glutathione 
reductase. Together these results suggest that Txnrd2 may also inhabit roles beyond Txn2 reduction. 
However, despite its similarity to Txnrd1, the catalogue of confirmed substrates for Txnrd2 is 
considerably smaller, with Txn2 considered the most efficiently reduced substrate. Whether this is 
due to structural differences of key residues around the redox active site of Txnrd2 or because of a 
different pH in mitochondria remains to be explained 21. Possibly the identification of Txnrd2-specific 
substrates is solely limited due to the reduced variety of target candidates in the mitochondria 
compared to the cytosol. 
 
1.3 Vasculature 
Blood vessels serve to transport blood and its constituents pumped from the heart to the tissues and 
organs throughout the body. In mammals, the Aorta carries the bulk of blood expelled from the heart 
to the body, branching into muscular and adaptive arteries and ever smaller arterioles until the 
smallest vessels – the capillaries – are reached. Traversing the thin walls of the capillaries the 
transported oxygen, nutrients and other compounds move into the tissue and the exchange of 
metabolites for elimination occurs. The venous system, consisting of vessels with thinner, more 
distensible and less muscular walls then carries the blood back to the heart via small venules, larger 
veins and the venae cavae. 
Blood vessels are constantly exposed to dynamic changes in volume, speed of flow and, due to their 
closed nature, pressures. For these reasons it is essential for blood vessels to be able to adapt. Short-
term responses include vasodilatation and vasoconstriction and long-term adaptation to changed 
haemodynamics is achieved by alterations in vessel wall composition and thickness. To understand 
how these processes are initiated and regulated, the structure of blood vessels and signalling 
processes involved must be considered. 
1.3.1 Structure of blood vessels 
Depending on vessel type (artery or vein) and size (artery vs. arteriole vs. capillary) blood vessels 
consist of up to three layers: the tunica intima (innermost), tunica media (middle) and the tunica 
adventitia (outer layer), as displayed in Figure 1-3. The intima consists of endothelial cells (ECs) and 
the basal lamina, while the media is composed of contractile vascular smooth muscle cells (VSMCs) 
surrounded by collagen and elastin fibres, the latter constituting the boundary of this layer in form of 
the external elastic lamina. Finally, the adventitia, consisting mainly of connective tissue, tethers the 
Introduction 
8 
 
vessel to the surrounding tissue 41. The smaller a vessel the fewer layers of muscle cells it contains in 
its wall. Thus, a capillary, for example, consists only of a single layer of ECs and the basal lamina, 
lacking smooth muscle cells altogether. 
 
Figure 1-3: Wall structure of a blood vessel. Image adapted from Rowley et al., 2008 42. 
 
1.3.1.1 Endothelial Cells 
Endothelial cells form the inner lining and are thus present in every blood vessel, from capillary to 
artery and vein. Therefore, they are directly exposed to the blood and its constituents, and as such 
regulate the transvascular movements of small molecules, can change vascular permeability as 
required, for example to allow the infiltration of leukocytes into the tissue, and can influence cells in 
other layers as well as circulating blood components in a paracrine and endocrine manner 43. ECs are 
critical in maintaining vessel patency; a deregulation of coagulation via ECs can lead to thrombosis 
and atherosclerosis. Furthermore, ECs are exposed to haemodynamic forces in response to which 
they can produce and release vasoactive substances such as NO, leading to smooth muscle relaxation 
and vasodilatation. A dysfunctional endothelium can thus result in the development of hypertension, 
thereby initiating a myriad of possible pathological conditions ranging from heart failure to renal 
dysfunction.  
While every cell of the vessel wall experiences stretch, for example to accommodate a change in 
pressure, ECs are the only cells of the vasculature exposed to changes in flow velocity, and as such 
are the sensors of fluid shear stress (FSS). FSS is the longitudinally acting force exerted on the 
endothelium by the friction the blood flow produces and has been proposed as an initial stimulus for 
vascular remodelling, the adaptation of the vessel wall to changes in haemodynamic forces and 
metabolic demands 44, 45. How the endothelium senses FSS and which receptors and/or transducers 
are responsible is still under investigation. Structures on the apical surface of the endothelium, such 
as ion channels, G-Protein coupled receptors and receptor tyrosine kinases have been implicated as 
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well as integrins and focal adhesion kinases at the cell/matrix interface or proteins present within 
cell-cell junctions, such as PECAM1 46. 
1.3.1.2 Vascular smooth muscle cells 
Vascular smooth muscle cells are responsible for the contractility of blood vessels and are therefore 
critical for the dynamic changes in vessel diameter and thus vessel conductance. The main function 
of a mature VSMC is contraction but these cells can also acquire a synthetic phenotype in which they 
significantly contribute to adaptive responses of blood vessels due to their plasticity and the 
production of matrix components 47. As discussed in the above section, VSMCs especially require ECs 
to regulate their response to alterations in FSS.  
1.3.2 Remodelling of blood vessels 
In order to accommodate biomechanical changes, blood vessels can respond quickly, for example by 
vasodilatation or contraction. If an alteration in a biomechanical variable persists, however, long-
term adjustments of the vessel wall must occur. Thus, capillaries can regress if they are no longer 
required or angiogenesis, the sprouting of new capillaries, can occur in order to maintain or establish 
perfusion to tissues requiring more oxygen and nutrients or to remove excess metabolites that could 
otherwise accumulate and be damaging. Likewise, arterioles must respond to chronic changes, for 
example by arteriogenesis, the remodelling of the vessel wall. 
1.3.2.1 Angiogenesis 
Sprouting of new capillaries is a process that can be as favourable as it can be damaging, depending 
on the tissue and the reason for capillary growth. A diabetic patient with an underperfused limb, for 
example, could benefit from the establishment of additional capillary networks. In cancer, on the 
other side, angiogenesis precedes the excessive growth of tumours by supplying vital blood-borne 
molecules. For these reasons, angiogenesis has received considerable attention and laboratories 
investigating numerous disease states have focussed efforts on elucidating the mechanisms involved. 
The initiation of angiogenesis is generally believed to occur in response to hypoxia 48. Low levels of 
oxygen stabilise the transcription factor Hypoxia-inducible factor-1α (HIF-1α) which, in turn, 
increases the transcription of members of the family of vascular endothelial growth factors (VEGF), 
the most important being VEGF-A 49. Binding to and activation of its tyrosine receptor kinase VEGFR2 
then stimulates EC proliferation, migration and sprouting, all hallmarks of angiogenesis 50. Of course, 
these processes must be tightly regulated and depend not only of the release of VEGF-A in response 
to HIF-1α stabilisation and subsequent activation of VEGFR2. Rather, the formation of new capillaries 
requires the presence of at least a provisional scaffold favourable for migrating ECs which is created 
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by the extravasation of plasma proteins and activation of matrix metalloproteinases, the proteolytic 
release and activation of bound VEGF isoforms from the extracellular matrix, loosening of EC-cell 
contacts, and a cascade involving the activation or deactivation of compounds regulating further 
sprouting, such as angiopoietin 1 (Ang1), other members of the VEGF family, fibroblast and platelet-
derived growth factors, angiostatin and endostatin 49, 50. Ultimately, the vessels must mature by 
forming a functional lumen and fuse with the existing vessels which also requires a finely tuned 
coordination of VEGF isoforms, Ang1 and integrins as well as become stabilised by the recruitment of 
perivascular cells, in particular pericytes, to the basolateral surface 49. 
Since ROS, apart from their detrimental effects at high, dysregulated levels, participate in important 
signalling cascades, it is not surprising to find several reports in the literature describing their 
contribution to the initiation and regulation of angiogenesis. The molecular background of ROS-
mediated effects on vascular remodelling will be discussed in detail in the following section. 
1.3.2.2 Arteriogenesis  
In contrast to angiogenesis, where new capillaries sprout from an existing network in response to 
hypoxia, arteriogenesis as such does not involve the de novo formation of vessels. Rather, pre-
existing vessels grow to larger conductance vessels in order to maintain or improve compromised 
tissue perfusion and meet a tissue’s metabolic demands following the gradual obstruction of a major 
feeding vessel as is the case, e.g. in coronary heart disease. Arteriogenesis occurs naturally in slowly 
progressing peripheral artery occlusion or other cardiovascular diseases characterised by occlusion of 
main blood vessels. For this reason some patients experience no or only mild symptoms despite 
significant occlusions of essential vessels 51. Today, pharmacological stimulation of arteriogenesis is 
being investigated as a possible therapeutic option to overcome limitations in the treatment of 
occlusive vascular diseases, either to minimise invasive surgery or as an alternative to standard 
therapies where contraindications or untreatable lesions prevent successful restoration of tissue 
perfusion 51. 
A simplified view would be to condense the stimulatory mechanisms involved in arteriogenesis to 
changes in haemodynamic forces, such as a drop in pressure across a vessel’s length, increased FSS 
and cyclic stretch. However, the regulation and progression of arteriogenesis requires a finely tuned 
molecular machinery and the participation of a multitude of other factors and perivascular cells. 
Initial investigations of arteriogenesis were hampered by the expectation that the regulation will 
share similarities with angiogenesis 51. In contrast to angiogenesis, however, arteriogenesis has been 
shown to occur independently of a drop in O2 tension and subsequent hypoxic signalling, and does 
not involve, at least directly, an increase in VEGF 52. Rather, it has been suggested that an increase in 
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FSS is the main driving force, at least in the initial phases of arteriogenesis. Increasing evidence 
supports the suggestion that the occlusion of a conduit vessel indeed causes an increase in flow 
velocity in collateral vessels due to the sudden pressure drop between the prestenotic high pressure 
bed and the poststenotic low pressure bed 53. It is well established that FSS can initiate complex 
signalling cascades, leading to a multifaceted response of the whole vessel. However, the effects of 
FSS on arteriogenesis upon flow obstruction in other vessels are often incomplete. Indeed, 
investigations on this topic consistently report that, while the remodelling of collateral vessels can 
provide a certain degree of compensation for stenosis, re-perfusion to levels equivalent to pre-
stenotic values is rarely achieved. Rather, collateral development ceases before optimal adaptation is 
achieved 54. This is most likely due to the flow-mediated dilation elicited by endothelial autacoids 
released upon the increase in FSS: release and subsequent relaxation of VSMCs leads to an increase 
in vessel diameter which is inversely proportional to FSS by the third power, ultimately producing a 
drop in FSS 53, 55. This endothelial-initiated dilation is mediated by NO, prostacyclin PGI2, 
endothelium-derived hyperpolarising factor (EDHF) and hydrogen peroxide (H2O2) 
56. Increased FSS 
results in a sustained production and release of NO from ECs until the subsequent vasodilatation is 
sufficient to return FSS to homeostatic levels 56. This prolonged effect is in stark contrast to NO 
release upon receptor stimulation and is suggested to occur via the phosphorylation of specific serine 
residues of endothelial nitric oxide synthase (eNOS) by phosphatidylinositol 3-kinase and the serine 
kinase Akt 57. While the identity and exact mode of action of EDHF is still extensively debated, it 
appears as a common denominator that involves potassium and possibly calcium-dependent 
potassium channels, ultimately hyperpolarising and relaxing vascular VSMCs 56. Finally, ROS can also 
exert vasodilatory effects 58, 59. During flow-mediated dilatation of human coronary resistance 
arteries, superoxide (O2
-•) production in the electron transport chain (ETC) complexes I and III of EC 
mitochondria increases, leading to augmented production and release of H2O2 
58. The dilatation of 
vessels subsequent to the release of H2O2 has been suggested to occur via a mechanism involving 
calcium-dependent activation of eNOS, release of NO, increase in soluble guanylyl cyclase and 
formation of cyclic guanosine monophosphate (cGMP) 59. 
Of course FSS, a mechanical force experienced only by the endothelium, may be the major player in 
the initiation of arteriogenesis but cannot serve as the only stimulus for a blood vessel to remodel. 
Other, non-endothelial factors also play a role, such as the effect on wall tension as a result of flow-
mediated dilation and the infiltration of inflammatory cells, especially monocytes 45, 60. 
Principally, a homeostatic level of wall tension provides optimal conditions for VSMCs. The Law  
of Laplace describes the relation of wall tension (T), pressure (P), radius (r) and wall  
thickness (w) ( ) and must be considered in this setting: an increase in vessel radius, as 
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occurs during flow-mediated vasodilatation, invariably increases wall tension. In order to maintain 
this radius but also return wall tension to homeostatic values, an increase in wall thickness occurs 61. 
As increases in FSS result in the dilation of vessels, the impact of flow on wall tension must also be 
considered in arteriogenesis. Indeed, prolonged periods of vasodilatation resulting from augmented 
tissue perfusion requirements ultimately lead to outward remodelling, i.e. an increase in luminal 
diameter, and this has been shown to occur both in vitro and in vivo 62. For example, isolated 
resistance vessels receiving the calcium channel blocker amlodipine for three days to cause 
prolonged vasodilatation developed an increase in passive diameter 63. In vivo, Unthank and 
colleagues reported that the diameters of collaterals had significantly increased in a model of 
mesenteric arteriole occlusion within one week 64. In a parallel study, the authors could also show 
that this increase in luminal diameter was greatest at sites exposed to the highest levels of flow and, 
most importantly in the concept of arteriogenesis, that this was accompanied by significant increases 
in cross-sectional medial area 65. The observed increase in medial thickness was produced via both 
endothelial and VSMC proliferation, ultimately returning the ratio of medial thickness : luminal radius 
to normal levels and thus also homeostatic wall tension.  
In addition to the generation of endothelial autacoids and vasodilatation discussed above, FSS has 
also been reported to alter the expression of numerous genes in ECs 66. Moreover, the expression of 
adhesion molecules, in particular the intercellular adhesion molecule-1 (ICAM-1) and the vascular cell 
adhesion molecule-1 (VCAM-1) are reported to be upregulated in ECs upon increased FSS, whereas 
the latter has also been reported to decrease upon FSS 60, 67-69. Similarly, the expression of the 
chemokine monocyte chemotactic protein-1 (MCP-1) has also been reported to increase in collateral 
vessels on both the mRNA as well as on the protein levels in response to FSS 60, 70. Together with the 
adhesion molecules ICAM-1 and VCAM-1, MCP-1 is now considered a vital component of pro-
arteriogenic processes by attracting and facilitating the transmigration of monocytes 67. However, 
this is a topic of substantial debate as the increased levels of FSS characteristic for arterioles are 
certainly not an environment favourable for cellular adhesion processes. Regardless of the site of 
attachment and transmigration, evidence supports the involvement of monocytes in arteriogenesis: 
Infusion of MCP-1 during hind-limb ischemia can significantly improve arteriogenesis 54. Furthermore, 
in the same study it was shown that the inhibition of ICAM-1 by a monoclonal antibody against the 
adhesion molecule significantly attenuated the beneficial effect of exogenous MCP-1. It is likely that 
the pro-arteriogenic properties of monocyte infiltration are due to their production and release of 
growth factors, especially tumour necrosis factor alpha (TNF-α) and basic fibroblast growth  
factor (bFGF) 70. 
Unlike the shear stress-dependent expression of ICAM-1 and VCAM-1, MCP-1 expression is not 
increased in ECs upon increased FSS. Actually, in isolated human umbilical vein ECs the expression of 
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MCP-1 mRNA decreased upon exposure to FSS 60, 66. It rather appears that the increased wall tension 
upon flow-induced dilation is the driving force for increased MCP-1 expression. Demicheva and 
colleagues showed that cyclic stretch, as a surrogate for increased wall tension, increased MCP-1 
expression on the mRNA and protein levels in both ECs as well as VSMCs in vitro 60. In isolated 
vessels, MCP-1 mRNA was increased 24 hours after the onset of arteriogenesis and even remained 
high after seven days 60. Furthermore, the authors could identify the VSMCs as the main source of 
MCP-1 protein expression. Finally, it was demonstrated that the cyclic stretch-induced upregulation 
of ICAM-1, VCAM-1 and MCP-1 was mediated by the increased activity of the stress-responsive 
transcription factor activator protein 1 (AP-1) 60. A possible pathway how the signals produced by 
growth factors, wall tension and FSS are integrated into an arteriogenic response was presented by 
Eitenmuller and colleagues in 2006 who provided evidence for the involvement of three potential 
signalling pathways. They showed a marked increase in phosphorylation of Ras and ERK as well as an 
upregulation of Ras protein levels, a pathway which translates growth factor signals to cellular 
proliferation processes. Furthermore, they described the involvement of the Rho pathway and 
especially RhoA which is commonly involved in cytoskeletal rearrangement, processes invariably 
engaged with cellular mobility and thus collateral development. Finally, they also discussed the 
somewhat enigmatic involvement of NO in the transmission of growth signals – after all, NO is well-
known for its antiproliferative effects. However, NO is at least required to mediate the flow-
dependent dilation following alterations in FSS and the authors suggest that NO can participate in the 
pro-arteriogenic processes by activating the Rho pathway 71. 
Finally, in the later stages of arteriogenesis, the surrounding matrix structures must give way to the 
growing structures and also provide support for the expanding vessel. This is achieved by the initial 
breakdown of elastic lamina and restructuring of the matrix constituents, achieved most likely via the 
increased expression and activity of various matrix metalloproteinases (MMPs), in particular MMP-2 
and MMP-9 72, 73. 
Considering the variety and this by far not exhaustive description of factors implicated in the 
initiation and progression of the processes involved in arteriogenesis and the delicacy of its 
regulation, it is not unexpected that ROS participate or can deregulate collateral vessel development. 
As for angiogenesis, the implication of ROS in arteriogenesis will be introduced in the following 
section. 
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1.4 Reactive oxygen species in vascular remodelling 
In vivo, low levels of H2O2 have been shown to activate proliferative responses in ECs via the 
activation of the angiogenic transcription factors NFκB, AP-1 and ets-1 74, 75. VEGF genes have binding 
sites for NFκB and AP-1 in their promoter sequences which is in line with findings showing that H2O2 
dose-dependently increases VEGF mRNA 76. A number of cancer cells have been reported to 
constitutively generate H2O2 in vivo and this can have a considerable influence on angiogenesis, both 
via the induction of VEGF transcription as well as through the inhibition of the tumour suppressor 
PTEN 77-79. Such a H2O2-dependent increase in VEGF production has also been reported to occur in 
macrophages, cells that migrate to sites of inflammation where angiogenesis is usually required 80. 
A possible molecular link between oxygen radicals and angiogenesis has recently been described and 
involves the stabilisation of HIF-1α. This oxygen-dependent transcription factor is rapidly ubiquinated 
under normoxia by the E3 ubiquitin ligase complex which is under control of the von Hippel-Landau 
tumour suppressor protein (pVHL) 81, 82. Under normoxic conditions, proline residues in HIF-1α are 
hydroxylated by the prolyl hydroxylase 2 (PHD2). This hydroxylproline residue is recognised by pVHL, 
leading to rapid degradation of HIF-1α. PHD2 requires the presence of the essential cofactors O2, Fe
2+ 
and 2-oxoglutarate in order to hydroxylate HIF-1α and is therefore considered an influential oxygen 
sensor 82. Thus, if oxygen concentrations in the cytosol decrease (due to tissue hypoxia or increased 
O2 consumption by the mitochondria for oxidative phosphorylation), PHD2 cannot destabilise HIF-1α, 
leading to its accumulation, transmigration to the nucleus and, ultimately, transcription of its more 
than 100 target genes, including other transcription factor which can further amplify the effects of 
HIF-1α 83.  
One of the other essential co-factors for PHD2 performance, Fe2+, is susceptible to oxidation by ROS. 
An increase in its positive charge (Fe3+) renders it unavailable for PHD2 catalytic activity 84. In 
situations with little available oxygen it appears plausible that ROS production decreases so the 
charge of Fe2+ should remain favourable for PHD2 activity. Paradoxically, despite a decrease of 
oxygen availability during hypoxia, ROS production increases as a stress response 85. This occurs in a 
biphasic manner, the first, quick effect possibly involving a deregulation of the mitochondrial 
complex III of the ETC, leads to an increase in ROS, oxidation of Fe2+ to Fe3+ and inhibition of PHD2 
catalytic activity, ultimately resulting in HIF-1α stabilisation and transcription of target genes. A 
second, time-delayed production of ROS via NADPH oxidase activation has been suggested to occur 
in response to the resulting increase in VEGF-A levels and binding to VEGFR2 85. 
While this regulatory system involving PHD2 and its oxygen and ROS-sensitive co-factors appears 
sound, and evidence, such as the activation of hypoxic signalling by exogenous H2O2 during normoxia, 
strongly supports the system discussed above, recent studies have shown that post-translational 
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modification of HIF-1α is more complex. For example, the HIF asparaginyl hydroxylase Factor 
inhibiting HIF (FIH) can be modified by peroxides at significantly lower levels than required to affect 
PHD2, suggesting a much lower sensitivity of PHDs to peroxide-dependent regulation. On the other 
hand, levels of ROS sufficient to inhibit PHD2 activity have no effects on FIH, suggesting that ROS do 
not play, at least not a direct role in HIF-1α stabilisation 86. In support of this, it was recently 
communicated that the production of ROS from isolated mitochondria actually decreases in response 
to hypoxia and that this occurs in an O2 concentration-dependent manner 
87.  
Both the cytosolic thioredoxin system and the mitochondrial equivalent potentially participate in 
angiogenesis. As mentioned previously, Txn1 has a dual role in the regulation of NFκB, a transcription 
factor affecting numerous angiogenic genes. Reduced Txn1 also directly interferes with the activity of 
ASK1 and elevated levels of oxidative stress can lead to the dissociation of the reduced Txn1 from the 
ASK1 signalosome, thereby enabling it to participate in apoptotic pathways 88, 89. Txn1 has also been 
reported to modify the activity of MMPs and their inhibitors, both enzymes required for the 
rearrangement of the extracellular scaffold supporting the newly formed vessels 90. 
In the previous section, the implication of Txnrd1 in a number of cancers was introduced. While 
cancer cells themselves express increased levels of Txnrd1 and strategies to combat tumour growth 
by inhibiting Txnrd1 are being developed, reports on an involvement of Txnrds on angiogenesis per 
se are few. A recent report using gold compounds as inhibitors of Txnrd1 showed an antiangiogenic 
effect in developing zebrafish 91. However, whether this effect was due to Txnrd1 inhibition in 
endothelial or other cells of the vasculature remains elusive. Furthermore, at which level 
angiogenesis was impaired (e.g. ROS, PHD2 or HIF-1α) was not investigated. To date, no reports on 
the possible direct involvement of Txnrd2 on angiogenesis have been published.  
In summary, the net output of ECs in response to an angiogenic stimulus cannot be explained solely 
by viewing only oxygen availability, production of ROS or the synthesis of proteins required for 
cellular migration, tube formation and stabilisation of immature vessels. Rather, it seems an 
integrated and highly regulated response occurs, ideally leading to a response that is beneficial to the 
tissue but also to the organism as a whole. 
 
Since many of the pathways and mediators implicated in vascular remodelling are impacted upon by 
their redox status, it is not surprising to find that ROS can participate in and/or modulate vascular 
growth in collateral vessels 92. However, the literature on the involvement of ROS on arteriogenesis is 
more limited than in the angiogenic situation, possibly due to the biomechanical nature of this type 
of vascular remodelling or the contribution of so many different cells. Of course, many of the effects 
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ROS exert on ECs discussed above in the context of angiogenesis may also be implicated in 
arteriogenesis. Additionally, there are some reports on the impact of ROS specifically on 
arteriogenesis. As described, FSS is thought as an initial stimulus for arteriogenesis and, despite this 
being a biomechanical force, numerous molecules are altered in response to changes in flow 
characteristics. More specifically, Laurindo et al. measured an increase in ROS production in ECs 
exposed to alterations in flow in intact rabbit aortas by electron spin resonance spectroscopy 93. In 
particular H2O2 was found in subsequent studies to increase in response to alterations in FSS 
58, 59. 
Interestingly, the effects of H2O2 also extend beyond the ECs as it has been shown to be released 
from ECs exposed to FSS and can thus also affect VSMCs 94. This is of particular importance in the 
context of remodelling of the vascular wall as H2O2 from endothelial sources increases placenta 
growth factor (PLGF) mRNA and protein expression in VSMCs. Furthermore, PLGF favours the 
recruitment of monocytes to the vascular wall, which inhabit central roles in the progression of 
arteriogenesis 95.  
Above, the transcription factor AP-1 was described as being activated by H2O2. Activation of AP-1 
leads to the production of vascular growth factors, such as ICAM-1 60. Thus, changes in FSS may not 
only initiate arteriogenesis via the subsequent vasodilation but also by increasing the synthesis and 
release of growth factors essential for vascular remodelling.  
Furthermore, ROS have been implicated in the regulation of MMP gene expression and activation 96. 
Indeed, elevated ROS have been described to increase the deposition of matrix proteins 97. Since ROS 
are released from sheared ECs and react with thiol groups, such as those present in the propeptide 
domain of MMPs, it is possible that increases in H2O2 may modulate the extracellular matrix 
composition and/or structure by altering the activity of MMPs 98. Interestingly, in the media of 
VSMCs exposed to increasing concentrations of H2O2 a biphasic effect on MMP-2 activation was 
observed: while low doses (4 µM) lead to an increase in MMP-2 activity, concentrations above 10 µM 
H2O2 inactivated MMP-2 
98. This further supports the presumption that ROS participate in many 
processes as long as they are maintained at tolerable concentrations.  
The detrimental effects of excessive ROS can be observed in many processes in aging, as ROS levels 
increase with senescence 99, 100. Therapeutically this is of particular importance as many cardio-
vascular diseases commonly occur in older individuals and the increased production of ROS can 
impair patient recovery. Accordingly, in a mesenteric collateral development model in the rat, 
vascular remodelling was impaired in older animals and this could be improved by the administration 
of antioxidants 101, 102. Hypertension, often associated with oxidative stress, has also been shown to 
impair arteriogenesis in the same rat model of mesenteric collateral growth. Here the administration 
of antioxidant therapy also ameliorated the detrimental effects of excess ROS 103, 104. Since ROS can 
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participate in numerous signalling pathways, can act as second messengers and regulate the activity 
of several proteins, it is near impossible to identify a single mechanism by which excess ROS can 
impair arteriogenesis. One possibility is the reduced bioavailability of NO, required for example for 
the vasodilatory response to increased FSS, which occurs through its rapid oxidative inactivation  
by excess O2
-•, resulting in a blunted vasodilatory capacity and the production of  
peroxynitrite (ONOO-) 105. Additionally, excessive production or inadequate antioxidative defense 
against ROS as seen with increasing age, can lead to the uncoupling of eNOS. Possibly caused by the 
oxidation of the eNOS cofactor Tetrahydrobiopterin (BH4) by ONOO
-, uncoupled eNOS produces O2
-• 
rather than NO, thereby increasing the oxidative burden even more 106.  
As for the involvement of the thioredoxin family in arteriogenesis, little is known. As mentioned 
previously, overexpression of Txn2 improves arteriogenesis in a murine hind-limb ischemia model 20. 
Models investigating other vascular remodelling processes such as pathological changes in response 
to hypertension or the development of atherosclerosis also provide support for the involvement of 
these endogenous antioxidants in vascular remodelling. Thus, overexpression of Txn2 also resulted in 
a blunted vasoconstrictive effect of Angiotensin II 19. In a similar study, Txn2 transgenesis produced 
an attenuated basal mean arterial blood pressure as well as end diastolic and end systolic pressures. 
In this study, increases in NO bioavailability and improved endothelium-dependent vasodilation were 
also observed. Additionally, these transgenics, when crossed with Apolipoprotein E-deficient mice, 
displayed fewer atherosclerotic lesions than their wildtype counterparts 107.  
 
1.5 Endothelial mitochondria in vascular remodelling 
Considering that mitochondria are one of the main sources of ROS in a cell and these radicals, as 
described above, can both participate in fundamental cellular processes but also cause detrimental 
damage, it is necessary to consider the contribution of this organelle in processes involved in vascular 
remodelling. While in most cells mitochondria are highly dependent on O2 to meet energy needs by 
the synthesis of adenosine triphosphate (ATP) via the ETC, endothelial mitochondria produce up to 
75% of their ATP via anaerobic glycolysis 108. In contrast to other, highly aerobic cells, mitochondria 
constitute only 5% of the mass of an EC 109. Since the energy production via the ETC is only of minor 
relevance, the capacity of endothelial mitochondria to produce ROS and thus participate in other 
processes such as signalling or apoptosis was, to a certain degree, neglected 110. Presently, however, 
endothelial mitochondria have been implicated in a range of pathological conditions of the 
vasculature such as atherosclerosis, diabetes and reperfusion injury, thereby highlighting the need to 
better understand the role of these organelles in the otherwise anaerobic endothelium 109. Of course, 
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as a producer of ROS, mitochondria can contribute to all the effects discussed above on oxidative 
signalling and stress. In addition, mitochondria have been described to be able to substantially 
modulate intracellular Ca2+ handling. Ca2+ inhabits central roles in many processes, ranging from 
eNOS activation and concomitant NO syntheses and vasodilatation to its function as a second 
messenger, and is therefore of considerable importance in the endothelium. Endothelial 
mitochondria, initially thought as a passive sink for Ca2+, actually actively participate in cellular Ca2+ 
homeostasis, the extent of which can be modulated by mitochondrial ROS 109, 110. For example, 
extracellular H2O2 has been shown to increase mitochondrial Ca
2+ concentration in excess of the 
increase in the cytosol of ECs. Furthermore, this appears in part to be due to an impairment of the 
mitochondrial Ca2+/Na+ exchanger which expels Ca2+ from the organelle, leading to an accumulation 
of Ca2+. Considering that mitochondria can pass Ca2+ to the endoplasmic reticulum (ER) to replenish 
its stores, oxidative interference with the mitochondrial Ca2+/Na+ exchanger can also severely limit ER 
function, leading to both mitochondrial and ER dysfunction 111, 112.  
A determinant of the electrochemical potential gradient driving molecules such as Ca2+, other ions 
and proteins from the cytosol into the mitochondria is the mitochondrial membrane  
potential (ΔΨm) 110. The ΔΨm resides around -180 to -220 mV and is the product of the reductive 
movement of protons via the ETC complexes across the inner membrane into the intermembrane 
space from where they are harvested by ATP synthase to produce ATP 113. As such, the charge of the 
ΔΨm can be indicative of mitochondrial health. Consequently, a decrease in the ΔΨm can attenuate 
the accumulation of Ca2+ (and other molecules) in the mitochondria in addition to the reduction in 
Ca2+ funnelling to the ER due to the oxidative stress-impaired Ca2+/Na+ exchanger 110. 
It is commonly reported that a decrease in ΔΨm increases O2
-• production from mitochondrial 
sources. Interestingly, it has now also been described that the charge of the ΔΨm in the 
mitochondria of kidney tumour cells was sensitive to intracellular H2O2 concentrations, suggesting 
that an increase in H2O2 may also disrupt the membrane potential 
114. 
Despite these findings, much of the role of mitochondria specifically in ECs remains to be fully 
elucidated. Studies investigating the modification of mitochondrial ROS production in ECs support a 
role for these organelles in vascular signalling, health and disease. Focus has been directed to the 
roles of the ETC, the NADPH oxidases and the antioxidant enzymes SOD or catalase in the 
endothelium. Knowledge on the participation of the mitochondrial thioredoxin system in the defence 
against oxidative stress as well as in signalling processes is rather scarce and even less is known 
within the EC. Since this enzyme system, together with the glutathione system, is now considered the 
main H2O2 detoxifying axis in mitochondria, it is necessary to begin to elucidate its contribution  
in ECs 115.  
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1.6 Intention of the present work 
Until now research has mainly focussed on the Thioredoxins and the cytosolic form of Txnrd, Txnrd1. 
Especially the involvement of the cytosolic Txn system in cancer has received a lot of attention. Less 
effort has been directed to the thioredoxin systems in cardiac and especially vascular contexts. Thus, 
Txn1 has been shown to prevent cardiac hypertrophy and protect from reperfusion injury, its 
suppressor TXNIP has been implicated in the initiation of atherosclerosis, and Txn2 has been 
reported to decrease angiotensin II-induced ROS production and improve arteriogenesis and 
angiogenesis when overexpressed. On the other hand, less is known on the participation of the 
corresponding reductases in vascular processes 14-17, 19, 20. Nonetheless, a report on the inhibition of 
Txnrd1 portrayed an increase in protein S-nitrosylation and blunted endothelium-dependent 
vasodilatation in mouse aortic rings, suggesting an important involvement of Txnrds in the vascular 
compartment 35.  
In previous studies, our cooperation partner Marcus Conrad, together with us, has been able to 
demonstrate that Txnrd2 is essential for embryogenesis, in particular in heart development and 
function as well as in haematopoiesis 38. In subsequent studies, the investigation of Txnrd2 was 
advanced using fibroblasts isolated from Txnrd2 knockout mouse embryos. In these studies, the 
effect of Txnrd2 on cellular proliferation, oxidative stress, interaction with other antioxidants as well 
as tumour growth and tumour angiogenesis were explored 37, 116.  
In regard to Txnrd2 function, studies have converged mainly on cancer and, to a lesser degree, 
cardiac physiology. Vascular implications of Txnrd2 function remain unexplored.  
Therefore, using embryonic endothelial progenitor cells (eEPCs) lacking Txnrd2 and inducible 
endothelium-specific Txnrd2 knockout mice, the present study aims to unravel the role of the 
mitochondrial Txnrd in endothelial physiology, vascular homeostasis and vascular remodelling 
processes with the following hypotheses: 
 Txnrd2 deletion leads to increased oxidative stress in eEPCs 
 
 Mitochondrial health, represented by ΔΨm, is impaired in Txnrd2-lacking eEPCs 
 
 Endothelial-specific deletion blunts both angiogenesis as well as arteriogenesis in a mouse 
model of hind-limb ischemia 
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2 Methods and Materials 
 
2.1 Materials 
The monoclonal antibody against Txnrd2 was previously produced in collaboration with Dr. Elisabeth 
Kremmer and Dr. Tamara Perisic (Helmholtz Centre, Munich). By immunising rats with the Txnrd2-
specific peptide (VKLHISKRSGLEPTVTG) coupled to ovalbumin (OVA)/ Keyhole limpet hemocyanin 
(KHL) (Peptide Specialty Laboratories, Heidelberg, Germany), more than 30 hybridoma clones were 
obtained and immunoreactivity screened by western blotting. For this study, the supernatant of the 
hybridoma clone #1C4 was used. 
 
ANTIBODIES COMPANY 
anti-α-Tubulin Sigma-Aldrich GmbH, Taufkirchen, Germany 
Rabbit anti-ß-actin Sigma-Aldrich GmbH, Taufkirchen, Germany 
Rabbit anti-BiP New England Biolabs GmbH, Frankfurt/Main, Germany 
Rat anti-CD31 Acris Antibodies GmbH, Herford, Germany 
Rat anti-CD45 BD, Franklin Lakes, USA 
Mouse anti-GAPDH Merck-Millipore GmbH, Schwalbach/Ts., Germany 
anti-goat IgG H&L chain specific Merck KGaA, Darmstadt, Germany 
Rabbit anti-HIF-1α Acris Antibodies GmbH, Herford, Germany 
Rabbit anti-IRE-1α New England Biolabs GmbH, Frankfurt/Main, Germany 
anti-mouse IgG H&L chain specific 
Peroxidase Conjugate 
Calbiochem, Nottingham, UK 
Mouse anti-Nitrotyrosine Abcam, Cambridge, UK 
Rabbit anti-PDI New England Biolabs GmbH, Frankfurt/Main, Germany 
Rabbit anti-PHD2 New England Biolabs GmbH, Frankfurt/Main, Germany 
anti-rabbit IgG, H&L chain specific 
Peroxidase Conjugate 
Calbiochem, Nottingham, UK 
Peroxidase AffiniPure Goat Anti-Rat 
IgG (H+L) 
Dianova GmbH, Hamburg, Germany 
anti-rat IgG H&L Cy3-Conjugate Dianova GmbH, Hamburg, Germany 
anti-Txnrd2 monoclonal antisera #1C4 Dr. Elisabeth Kremmer, Helmholtz Centre, Munich, Germany 
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CELL CULTURE REAGENTS COMPANY 
ß-Mercaptoethanol  Invitrogen, Karlsruhe, Germany 
Dimethyl sulfoxide AppliChem GmbH, Darmstadt, Germany 
Dulbecco´s Modified Eagle Medium high glucose 
(4.5g/l glucose) 
Invitrogen, Karlsruhe, Germany 
Fetal calf serum Biochrom AG, Berlin, Germany 
Gelatine from porcine skin Sigma-Aldrich GmbH, Taufkirchen, Germany 
L-Glutamine, 200mM, liquid Invitrogen, Karlsruhe, Germany 
MEM non-essential amino acids (100x) Invitrogen, Karlsruhe, Germany 
Penicillin-Streptomycin Solution, 100mM Invitrogen, Karlsruhe, Germany 
Trypsin 0.05% (1x) EDTA 4Na, liquid Invitrogen, Karlsruhe, Germany 
 
CHEMICALS COMPANY 
2-Propanol Carl Roth GmbH & Co. KG, Heidelberg, Germany 
3-Morpholinopropanesulfonic acid AppliChem GmbH, Darmstadt, Germany 
Acetic Acid 100% Carl Roth GmbH & Co. KG, Heidelberg, Germany 
Acetone Carl Roth GmbH & Co. KG, Heidelberg, Germany 
Adenosine Sigma-Aldrich GmbH, Taufkirchen, Germany 
Agarose low EEO AppliChem GmbH, Darmstadt, Germany 
Aqua ad iniectabilia B. Braun Melsungen AG, Melsungen, Germany 
Bovine serum albumin (albumin fraction V) AppliChem GmbH, Darmstadt, Germany 
Bromphenol blue Sigma-Aldrich GmbH, Taufkirchen, Germany 
Calcium chloride dihydrate Sigma-Aldrich GmbH, Taufkirchen, Germany 
CellROX Life Technologies, Darmstadt, Germany 
CheLuminate-HRP PicoDetect AppliChem GmbH, Darmstadt, Germany 
Collagenase A Roche Applied Science, Mannheim, Germany 
Dimethyl sulphoxide Carl Roth GmbH & Co. KG, Heidelberg, Germany 
Disodium hydrogenphosphate AppliChem GmbH, Darmstadt, Germany 
dNTPs for PCR, premixed GE Healthcare, Freiburg, Germany 
Ethylenediaminetetraacetic acid AppliChem GmbH, Darmstadt, Germany 
Eosin G, 0.5% Carl Roth GmbH & Co. KG, Heidelberg, Germany 
Ethanol Merck KGaA, Darmstadt, Germany 
Forene® Abbott GmbH & Co KG, Wiesbaden, Germany 
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Gel Red Biotrend, Cologne, Germany 
Glucose AppliChem GmbH, Darmstadt, Germany 
Glycerol Sigma-Aldrich GmbH, Taufkirchen, Germany 
Goat Serum Sigma-Aldrich GmbH, Taufkirchen, Germany 
Haematoxylin solution, acidic Carl Roth GmbH & Co. KG, Heidelberg, Germany 
Hydrochloric acid Merck KGaA, Darmstadt, Germany 
JC-1 Life Technologies, Darmstadt, Germany 
Magnesium chloride AppliChem GmbH, Darmstadt, Germany 
Magnesium sulphate heptahydrate AppliChem GmbH, Darmstadt, Germany 
Methanol Carl Roth GmbH & Co. KG, Heidelberg, Germany 
Nonfat dried milk powder AppliChem GmbH, Darmstadt, Germany 
Page Ruler™ Prestained Protein Ladder Fermentas GmbH, St. Leon-Roth, Germany 
Paraformaldehyde Merck KGaA, Darmstadt, Germany 
peqGOLD 100 bp DNA ladder Peqlab, Erlangen, Germany 
Phenol/Chloroform/Isoamyl alcohol Carl Roth GmbH & Co. KG, Heidelberg, Germany 
Ponceau S Sigma-Aldrich GmbH, Taufkirchen, Germany 
Potassium acetate Merck KGaA, Darmstadt, Germany 
Potassium chloride AppliChem GmbH, Darmstadt, Germany 
Potassium cyanide Sigma-Aldrich GmbH, Taufkirchen, Germany 
Potassium dihydrogen phosphate Merck KGaA Darmstadt, Germany 
Roti-Histol Carl Roth GmbH & Co. KG, Heidelberg, Germany 
Sodium Nitroprusside (SNAP) Biotrend Chemikalien GmbH, Cologne, Germany 
Sodium chloride AppliChem GmbH, Darmstadt, Germany 
Sodium deoxycholate Sigma-Aldrich GmbH, Taufkirchen, Germany 
Sodium dodecyl sulfate Sigma-Aldrich GmbH, Taufkirchen, Germany 
Sodium fluoride Merck KGaA, Darmstadt, Germany 
Sodium hydroxide Merck KGaA, Darmstadt, Germany 
Sodium orthovanadate Enzo Life Sciences GmbH, Lörrach, Germany,  
Sodium phosphate monobasic monohydrate AppliChem GmbH, Darmstadt, Germany 
Sodium pyruvate Sigma-Aldrich GmbH, Taufkirchen, Germany 
SuperSignal® West Femto Substrate Thermo Fischer Scientific, Bonn, Germany 
Tamoxifen Sigma-Aldrich GmbH, Taufkirchen, Germany 
Tris AppliChem GmbH, Darmstadt, Germany 
Triton X-100 AppliChem GmbH, Darmstadt, Germany 
Tween 20 AppliChem GmbH, Darmstadt, Germany 
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VectaMount AQ Aqueous Mounting Medium Linaris GmbH, Dossenheim, Germany 
Vectashield HardSet Mounting Medium with 
DAPI 
Linaris GmbH, Dossenheim, Germany 
 
ENZYMES COMPANY 
Protease/Phosphatase Inhibitor Cocktail (100X) New England Biolabs GmbH, Frankfurt/Main, 
Germany 
Proteinase K Roche Applied Science, Mannheim, Germany 
Taq DNA polymerase Qiagen GmbH, Hilden, Germany 
 
KITS AND DISPOSABLES COMPANY 
8 – 16% Precise Tris-Glycine gels, 10x10 and  
8x10 cm Cassettes 
Perbio, Thermo Fischer Scientific, Bonn, Germany  
BCA™ Protein Assay Reagent A/B Thermo Fischer Scientific, Bonn, Germany 
Delimiting Pen Dako, Hamburg, Germany 
Parafilm M® Pechiney Plastic Packaging Company  
Perma-Hand Silk Suture Ethicon, Neuss, Germany 
Polypropylene tubes Greiner Bio-One, Frickenhausen; Germany 
QIAshredder Qiagen GmbH, Hilden, Germany 
Reverse Transcription System Promega GmbH, Mannheim, Germany 
RNase-Free DNase Set Qiagen GmbH, Hilden Germany 
RNeasy Mini Kit Qiagen GmbH, Hilden, Germany 
Silk braided suture (7-0) Pearsalls Ltd, Somerset, UK 
SuperFrost® Plus slides Thermo Fischer Scientific, Bonn, Germany 
Tissue-Tek® O.C.T. ™  Sakura, Zoeterwonde, Netherlands 
Vectastain ABC-Kit Elite Rat IgG Linaris GmbH, Dossenheim, Germany 
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OLIGONUCLEOTIDES FOR GENOTYPING SEQUENCE 
TR2_Del_for 5´-CACGACCAAGTGACAGCAATGCTG-3´ 
TR2_Del_rev 5´-CAGGCTCCTGTAGGCCCATTAAGGTGC-3´ 
TR2_Flox_for 5´-CAGGTCACTAGGCTGTAGAGTTTGC-3´ 
TR2_Flox_rev 5´-TTCACGGTGGCGGATAGGGATGC-3´ 
CRE 1 5´-GCCTGCATTACCGGTCGATGCAACGA-3’ 
CRE 2 5´-GTGGCAGATGGCGCGGCAACACCATT-3’ 
All DNA-oligonucleotides were obtained from Eurofins MWG Operon, Ebersberg, Germany. 
 
2.2 Animals 
Mice lacking Txnrd2 were established as described previously for other organs 39. In brief, inducible 
endothelial-specific deletion of Txnrd2 was achieved by crossing mice expressing LoxP-flanked 
Txnrd2 (flox) with mice expressing Cre recombinase (Cre) under control of the VE-Cadherin 
promoter. Induction of the knockout was achieved through i.p. administration of Tamoxifen (20 
mg/ml in neutral oil (medium chain triglycerides)) for 5 consecutive days for a total of 5 mg 
Tamoxifen per mouse. The induction was allowed to proceed for at least two weeks before 
experiments were performed. 
2.2.1 Genotyping 
The genotype of the Mice undergoing experimental procedures was established prior to their import 
from the animal holding facility to the laboratory by digesting of and the extraction of DNA from tail 
clippings.  
DNA was precipitated by immersing the tail clipping in 500 µl Lysis buffer containing Proteinase K in a 
Thermomixer (Eppendorf, Germany) set to 55°C and 700 rpm overnight. The following morning the 
temperature was increased to 85 °C for one hour to inactivate Proteinase K, followed by the addition 
of 500 µl Phenol/Chloroform to the homogenate, vortexing and centrifugation (14,000 rpm, 6 
minutes), after which an upper and a lower phase appeared in the supernatant. The upper phase was 
transferred to an eppendorf tube containing 2.5 volumes of 100% Ethanol and 5M NaCl, shaken and 
centrifuged (15,000 rpm, 10 minutes, 4°C). Having discarded the supernatant, the pellet was washed 
twice in 70% Ethanol and subsequently dried in a Thermomixer at 55°C. Finally, the pellet was 
dissolved in TE buffer and stored at -20°C until analysed by PCR (discussed below). 
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Tail lysis buffer 
EDTA 10 mM 
Tris-HCl, pH 7.6 10 mM 
SDS 0.5% 
NaCl 10 mM 
Proteinase K 15 µl/ ml lysis buffer 
 
After completion of experimental procedures and sacrificing of the mice, tail clippings were 
additionally obtained to ensure, by the method described above, the correct genotype of the mice.  
Furthermore, to confirm the successful deletion of Txnrd2 specifically in the endothelium, kidneys 
were removed, homogenised and digested in Collagenase A (2 mg/ml) for one hour at 37°C. The 
homogenate was centrifuged (1300 rpm, 10 min, 4°C) and the pellets washed twice by resuspension 
in 2% FCS in PBS and centrifugation. To isolate the ECs from the other cells present in the 
homogenate, the pellets were incubated with a rat anti-mouse CD31 antibody (1:100 in 2% FCS/PBS 
in a thermo shaker set to 4°C and 700 rpm for one hour). After an additional three washing steps, the 
CD31 antibody was conjugated to anti-rat-coated microbeads (concentration 1:5, Miltenyi Biotech, 
Bergisch Gladbach, Germany) by incubation in a thermo shaker set to 4°C and 700 rpm for one hour. 
Subsequently, samples were again washed three times by centrifugation and the homogenate 
applied to MACS® cell separation columns placed in a magnet (Miltenyi Biotech, Bergisch Gladbach, 
Germany). As the homogenate passes through the magnets, the CD31/microbead-labelled ECs are 
retained within the columns and the unwanted cells discarded. Once the entire volume had passed 
the columns, the magnets were removed and the retained ECs were flushed out of the columns. 
After a final centrifugation step, the EC-pellet was lysed in RIPA buffer and the presence of Txnrd2 
determined by western blot as described below. 
 
2.3 Hind-limb ischemia  
Occlusive artery disease is a common hallmark in a variety of diseases, such as myocardial infarction 
and stroke, which are characterised by an acute occlusion of conduit arteries and a resulting lack of 
perfusion to the downstream tissue. If perfusion is to be re-established in such conditions, blood flow 
must be restored. This can occur either by dissipation of the cause of the occlusion, for example by 
fibrinolytic processes. Another possibility to re-establish perfusion is for the blood to bypass the 
blocked vessel through other, pre-existing – collateral – arterioles.  
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Collateral arterioles bud off from the artery upstream of the site of occlusion and re-enter 
downstream. At the onset of occlusion, collateral arterioles experience the drop in downstream 
pressure in the artery as a pressure gradient across their length. As a result, blood flow through the 
collateral arterioles increases, thereby inducing a cascade of haemodynamic-sensitive responses.  
At a constant vessel diameter, an increase in flow is associated with an increase in FSS, the tension 
the viscous blood exerts on the endothelial layer of a vessel wall. While the impact of increased FSS 
on collateral artery remodelling is highly debated, another result of increased blood flow is pressure-
induced vasodilatation. Vasodilation stretches the vessel wall constituents: VSMC and ECs, but also 
extracellular matrix structures and the elastic lamina. In response, vascular wall cells proliferate in 
order to distribute the stretch-induced burden and re-establish homeostatic conditions. Invasion of 
inflammatory cells, especially monocytes, adds another stimulus for VSMC proliferation, thereby 
further enhancing the adaptive response. 
In the end, collateral arterioles of an occluded artery act as natural bypass vessels and can 
compensate, at least to a certain degree, the decrease in perfusion 117. 
Tissues downstream of the occlusion and dependent on vessel patency to maintain oxygen 
homeostasis can be subject to hypoxic conditions if perfusion is impaired for longer durations. 
Hypoxia is considered the main driving force for angiogenesis 49, the budding of new capillaries within 
an existing network.  
2.3.1 Surgery 
Hind-limb ischemia was induced by unilateral ligation of the right femoral artery as described in 
detail elsewhere 118. Briefly, Mice were anaesthetised by subcutaneous injection of Midazolam, 
Fentanyl and Medetomidine (Midazolam (5 mg/kg; Ratiopharm, Ulm, Germany), Fentanyl (0.05 
mg/kg; CuraMed, Karlsruhe, Germany), and Medetomidine (0.5 mg/kg; Pfizer, Karlsruhe, Germany)) 
and a Laser Doppler measurement performed (described below) to establish baseline hind-limb 
perfusion. Subsequently, both thighs were shaved and the femoral artery located. Through a small 
incision the femoral artery was isolated from the corresponding nerve and vein as well as connective 
tissue. Occlusion was performed on the right femoral artery by tying a thread around it just below 
the deep femoral branch. An in-animal sham-control was performed on the contralateral limb by 
placing the thread around the isolated femoral artery without tying a knot. Finally, the skin was 
closed with a surgical suture thread and animals allowed to recover in solitary cages after having 
received a mixture of Atipamezole, Naloxone and Flumazenil (Atipamezole (2.5 mg/kg; Pfizer, 
Karlsruhe, Germany), Naloxone (1.2 mg/kg; Inresa, Freiburg, Germany), and Flumazenil (0.5 mg/kg; 
Hoffmann-La-Roche, Grenzach-Wyhlen, Germany)) subcutaneously. 
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2.3.2 Laser Doppler Imaging (LDI) 
The extent of hind-limb perfusion was established prior to surgery, immediately thereafter as well as 
three and seven days after occlusion of the femoral artery. Unless mice were anaesthetised for 
surgery as described above, sedation was achieved by inhalation of isoflurane (Isoflurane 1 vol. %, O2 
1.5 l/min) throughout the measurement. Hind-limbs of mice were fixed with double-sided adhesive 
tape to a plate within a heated chamber (37°C). After an acclimatisation period of seven to ten 
minutes, LDI measurements of the hind-limbs were performed with the laser Doppler LDI 5061 
(Moor Instruments, Remagen, Germany) connected to a PC running the corresponding Moor 
Software Version 3.01. Equal-sized regions of interest were placed around the paws of the mice and 
perfusion (reflected in terms of colours, where warm colours represent high perfusion values and 
cold colours symbolise little perfusion) was assessed. To standardise LDI measurements, background 
tissue values were subtracted and results expressed as the perfusion ratio of the occluded hind-limb 
relative to the sham-operated limb. 
2.3.3 Tissue Harvesting & Processing 
After the final LDI measurement the adductor and calf muscles of the occluded and sham-operated 
limb were either excised directly or after maximal dilation of vessels and/or perfusion fixation as 
described below. After opening the abdominal cavity, the descending Aorta was catheterised with PE 
tubing and the vena cava was punctured to allow blood and the administered solutions to drain. 
Adenosine buffer (1 ml PBS, 5 mg bovine serum albumin, 1 mg adenosine) and, if paraffin sections 
were to be prepared, 4% paraformaldehyde solution were subsequently administered via the aortic 
catheter until the solution returned via the vena cava clear from blood. 
Removed muscles were embedded in either Tissue Tek and stored at -80°C for cryo preservation or 
embedded in paraffin following general protocols for subsequent histology and immunofluorescence 
studies.  
 
2.4 Arteriogenesis 
Paraffin-embedded adductor muscles were sectioned using a microtome (Biocut 2030, Reichert-Jung, 
Leica Microsystems, Wetzlar, Germany) in 5 – 6 µm thick slices and three sections, from each the 
medial, intermediate and lateral side of the muscle, placed on a microscope slide. Subsequently the 
slices were stained with haematoxylin and eosin as described in Table 2-1 to visualise cell nuclei and 
eosinophilic structures, such as cytoplasm and connective tissue. Since collateral vessels differ in 
their thickness across their course through the muscle, vessels at the height of the occlusion (i.e. the 
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intermediate section which is the narrowest area) were photographed at 400x magnification using a 
bright field microscope (BX41, Olympus, Hamburg, Germany) featuring a camera (Camedia C5050, 
Olympus) coupled to imaging software (DP-Soft v. 3.2, Olympus). Vessels were assessed for inner and 
outer vessel circumference using ImageJ software (1.43u, National Institutes of Health, USA). 
Measuring circumference allows the comparison of blood vessels irrespective of their shape and also 
permits the calculation of wall area, wall thickness and lumen using standard circle formulas 118. 
Table 2-1: Haematoxylin and eosin staining protocol 
Thaw slices at room temperature 5 min 
Rehydrate slices in PBS 5 minutes 
Stain with Harris haematoxylin 7 minutes 
Wash in demineralized water 17 minutes 
Stain with 0.1% Eosin 5 minutes 
Briefly wash in demineralized water 5 intermittent washes 
Dehydrate in 100% EtOH 2 minutes 
Immerse in Xylene 5 minutes 
Cover with mounting medium (Roti-Histol) and glass cover slips  
 
2.5 Angiogenesis 
Cryo-conserved calf (gastrocnemius) muscles were sectioned with a cryostat (Cryotome HM 560, 
Microm, Walldorf, Germany) in 10 µm thick slices and three slices from the anterior, posterior and 
intermediate region of the muscle placed on a microscope slide. Subsequently, they were fixed in ice-
cold acetone for 20 minutes and air-dried before being frozen at -20°C for storage. To assess 
angiogenesis, calf muscle cryosections were stained with an antibody raised against the endothelial 
membrane protein CD31 which, in turn, was detected with a Cy3-conjugated secondary antibody 
following the protocol outlined below (Table 2-2). 
Calf muscle cryosections were photographed using a camera (AxioCam, Zeiss, Munich, Germany) 
coupled to a fluorescence microscope (Axiophot, Zeiss) at 20x magnification. In order to be able to 
compare vessel density within and between individual mice, three distinct sites per slice were 
selected. Angiogenesis in these areas was then assessed by measuring CD31-positive areas using 
ImageJ software (1.43u, National Institutes of Health, USA). Results were expressed as the area 
fraction of the entire image. 
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Table 2-2: Immunofluorescence Staining Protocol 
Thaw sections at room temperature 10 – 15 min 
Rehydrate in PBS at room temperature ≥ 20 min 
Dry and cycle sections with liquid blocker pen  
Incubate with blocking solution 5 % BSA in PBS 30 min 
Incubate with rat anti-CD31 antibody (1:400 in blocking solution) at 4°C Over night 
Wash three times in PBS  Five min each 
Incubate with Cy3-conjugated goat anti-rat antibody (1:200 in blocking solution) at 
room temperature 
Two hours 
Wash three times in PBS  Five min each 
Mount coverslips with Vectashield DAPI  
 
2.6 Flow-mediated Dilatation 
To assess the vasodilatory capacity of the collateral arterioles from Txnrd2ECWT and Txnrd2ECKO mice in 
response to alterations in flow velocity, a protocol described in detail previously was applied with 
minor modifications 119. In brief, male Txnrd2ECWT and Txnrd2ECKO mice were euthanized by cervical 
dislocation. After removal of the skin of the thighs, the adductor muscle was carefully dissected and 
removed without damaging the vessels. During the whole procedure, the tissue was superfused by 
4°C cold 3-morpholinopropanesulphonic acid (MOPS)-buffered salt solution (composition below). 
Five hundred µm long sections of collateral arterioles without branches were carefully isolated and 
cleaned from connective tissue using a preparation microscope (M205A, Leica Microsystems, 
Wetzlar, Germany). In a temperature-controlled, MOPS-filled organ bath, collateral vessel sections 
were cannulated with glass micropipettes (Science Products, Hofheim, Germany) mounted on 
micromanipulators (World Precision Instruments, Berlin, Germany), which allowed three-dimensional 
adjustment of the pipettes. Via a three-way valve the open end of one pipette was connected to a 
silicone tube and a height-adjustable reservoir containing MOPS buffer. Initially, the reservoir was set 
to a height representing a transmural pressure in the vessel of 45 mmHg. The open end of the other 
micropipette was also connected to silicone tubing via a three-way valve to allow the outflow of the 
perfusion fluid (Figure 2-1). The setup was mounted on an inverted microscope (Diaphot 300, Nikon, 
Düsseldorf, Germany) and the vessel visualised at 20x magnification (D-APO 20 UV lens, Olympus, 
Hamburg, Germany) with a CCD camera (WAT-902B, Watec Newburgh, NY, USA). Inner and outer 
diameters of the collateral arteriole were continuously monitored with the commercial software 
Blood Vessel Analyser 300 (Hasotec, Rostock, Germany).  
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With both three-way valves open, collateral arterioles were precontracted to a level comparable to 
the in vivo situation by administration of 1 µM of the thromboxane mimetic, U46619 (Tocris, R&D 
Systems GmbH, Wiesbaden-Nordenstadt, Germany). To assess flow-mediated dilatation the position 
of the reservoir was adjusted to produce various pressures (7.5, 15, 25, 35, 45, 55 mmHg), thereby 
changing the flow velocity within the collateral arteriole. By continuously recording the changes in 
arteriole diameter, the effect of increased flow velocity on vasodilatation was assessed and analysed 
as the % dilation of the U46619-induced precontraction with the following formula: 
 
 
Figure 2-1: Representative setup for the measurement of flow-mediated dilatation.  By changing the 
height of the MOPS-reservoir depicted on the right the inflow pressure into the vessel was altered. When both 
three-way valves were open, the change in inflow pressure resulted in an alteration of flow velocity and 
consequently also vessel diameter. 
 
MOPS buffer 
NaCl 145 mM Pyruvate 2 mM 
KCl 4.7 mM EDTA 0.02 mM 
CaCl2 x 2 H2O 3 mM MOPS 3 mM 
MgSO4 x 7 H2O 1.17 mM Glucose 5 mM 
NaH2PO4 x 1 H2O 1.2 mM pH 7.4 
Sterile filtration 
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2.7 Cell Culture 
All cell culture-related work was carried out under sterile conditions using an air flow bench (Steril 
Compact VBH 48 C2, Foster Wheeler, Corsico, Italy). Furthermore, any reagents or instruments to be 
introduced to the sterile area were autoclaved (Vakulab, Münchener Medizin Mechanik GmbH, 
Munich or Varioklav®, HP Labortechnik, Oberschleißheim, Germany) and/or disinfected with Bacillol® 
AF (Paul Hartmann AG, Heidenheim, Germany). Cells were cultured in a humidified incubator 
(APT.line™ CB210, Binder, Tuttlingen, Germany) at a constant temperature of 37°C, 5% CO2  
and 20% O2. Cells were routinely monitored under a light microscope (IX50, Olympus, Hamburg, 
Germany). 
2.7.1 Embryonic endothelial progenitor cells 
Since primary mouse ECs are not available in ample amounts and do not allow multiple passaging, 
eEPCs were employed as a tool to investigate in vitro effects of Txnrd2 deletion.  
Embryonic EPCs had been isolated from embryos of pregnant heterozygous mice according to a 
protocol developed by Hatzopoulos et al.120 at embryonic day 7.5. eEPCs were cultured on 0.1% 
gelatine-coated plates at 37°C and 5 % CO2 in a humidified incubator in high glucose Dulbecco´s 
modified eagle´s medium (DMEM) supplemented with 10 % fetal calf serum (FCS), 1 % L-Glutamine 
(200 mM), 1 % penicillin/streptomycin, 1 % non-essential amino acids and 0.06% ß-Mercaptoethanol 
(50 mM). For serial passaging, eEPCs were washed with PBS, detached with trypsin and split in a ratio 
up to 1:6 every two days.  
To investigate oxidative stress-dependent effects, eEPCs were cultured in medium without ß-
Mercaptoethanol as this compound exhibits antioxidant properties. To this end, confluent cells were 
washed in PBS and cultured in high glucose DMEM supplemented with 20 % FCS as well as the above 
additions except ß-Mercaptoethanol. Medium was changed once daily for at least four consecutive 
days before experiments were performed. 
2.7.2 Cell Passaging and Harvesting 
eEPCs were cultured to 80 – 90% confluence, washed with PBS- and detached by adding 1 ml of 
Trypsin/EDTA solution per 10 cm dish. At 37°C, the proteolytic activity of trypsin and the chelating 
capacity of EDTA dissociate the cells within 5 minutes, a process which was checked under a light 
microscope. To stop the enzymatic activity of Trypsin, FCS-containing DMEM was added at a volume 
corresponding to at least the volume of Trypsin/EDTA. Depending on the experiment to be 
performed or whether cells were solely passaged to maintain growth, cells were split at ratios 
ranging from 1:2 to 1:6. 
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2.7.3 Determination of Cell Number 
Cells were trypsinised and collected in an appropriate amount of DMEM. Subsequently, 100 µl of cell 
suspension was added to 10 ml of NaCl and analysed by a Coulter Z2 Cell and Particle counter 
(Beckman Coulter, Krefeld, Germany). 
2.7.4 Cell Thawing and Cryo-conservation 
To maintain a sufficient supply of eEPCs in liquid nitrogen, cells were routinely expanded by serial 
passaging and subsequently cryo-conserved. Once cells had grown to near confluence they were 
collected by trypsination and centrifugation (1500 rpm, 5 minutes). The pellet was resolved in 
freezing medium, transferred to cryo-vials and stored at -80°C overnight before being transferred to 
liquid nitrogen for long-term storage.  
As required, cells were quickly defrosted in a water bath set to 37°C, transferred to a falcon tube 
containing standard DMEM as described above and centrifuged (1500 rpm, 5 minutes) to protect the 
cells from the DMSO in the freezing medium (see below). Following centrifugation, the pellet was 
resuspended in DMEM and transferred to a 10 cm dish. After 24 hours, cells were checked for 
viability using a light microscope and fresh medium added. 
Freezing Medium 
DMSO 10% 
in FCS  
 
2.8 Protein Biochemistry 
In order to study proteins in regard to their existence, quantity and potential post-translational 
modifications such as phosphorylation or nitration, western blotting experiments were performed. 
This technique employs Tris-Glycine SDS-PAGE electrophoresis to separate proteins depending on 
their molecular size. To achieve this, proteins must first be denatured by a combination of lysis 
buffer, heat and loading buffer. Denaturation of proteins exposes their hydrophobic regions which 
readily bind to SDS, thereby conferring a negative charge upon them 121. During electrophoresis the 
denatured, negatively charged proteins migrate toward the anode with varying speeds, depending 
on their size and the acrylamide concentration of the gel matrix. Thus, in a given period of time a 
large protein will traverse only a fraction of the distance a small protein can travel. 
2.8.1 Preparation of Protein Lysates 
Cells were grown to confluence, washed twice with PBS and incubated with lysis buffer for 10 
minutes on ice. Subsequently, any cells remaining attached to the dish were mechanically removed 
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using a rubber policeman and all cells transferred to an eppendorf tube. Depending on the protein of 
interest either a mild or harsh lysis buffer was employed, the main variation between buffers being 
the type of detergent used. The mild lysis buffer contained only one ionic detergent, sodium 
deoxycholate, whereas the harsh buffer, RIPA, also contains SDS as an additional ionic detergent and 
Triton X-100 as a non-ionic detergent. 
If a mild lysis buffer was employed, samples were further processed with an insulin syringe. Following 
lysis with RIPA buffer, samples were additionally sonicated (five seconds, 50% pulse). To remove 
remaining cell debris, lysates were centrifuged (13000 rpm, 10 minutes at 4°C) and the pellet 
discarded. Protein quantification was then performed either directly or after storage of the samples 
at -20°C. 
 
Mild Lysis Buffer  
 
Harsh Lysis Buffer (RIPA) 
NaCl 150 mM 
Triton X-100 1% 
Sodium deoxycholate 0.5% 
Sodium dodecyl sulphate (SDS) 0.1% 
Tris, pH 8.0 50 mM 
 
Protease and phosphatase inhibitors (Protease/Phosphatase Inhibitor Cocktail (100X)) were added to 
the lysis buffers immediately before use 
2.8.2 Protein Quantification 
Quantification of sample protein content was performed with the bicinchoninic assay BCA™ Protein 
Assay Reagent A/B with a standard curve ranging up to 2 mg/ml using bovine serum albumin 
supplied with the kit. Duplicate standards and samples were incubated at appropriate dilutions for 30 
minutes at 37°C with the BCA reagents (50 parts reagent A : 1 part reagent B) in 96-well plates and 
absorbance of the resulting BCA-copper complex detected at 550 nm with a plate reader (Infinite 
F200, Tecan, Crailsheim, Germany). The concentration of the samples was then calculated by linear 
regression of the standards and expressed in µg/ml. 
2.8.3 Immunoblotting 
To separate proteins solubilised in lysis buffer, SDS-Page electrophoresis was performed. Having 
established a sample’s protein concentration, a volume corresponding to 10 to 50 µg of protein per 
sample was mixed with 4x or 6x loading buffer and heated to 95°C for 10 minutes to denature the 
Tris, pH 7.4 20 mM 
NaCl 137 mM 
EDTA 2 mM 
Glycerol 10% 
Sodium deoxycholate 0.1%, added freshly 
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proteins. Brief centrifugation was performed to collect any precipitate formed on the walls and lid of 
the tubes. Samples were then loaded in 8-12 % gradient gels and proteins separated depending on 
their molecular weight using a Mighty Small II SE 250/SE 260 mini vertical unit (Amersham, GE 
Healthcare, Freiburg, Germany) connected to a power supply unit set to 300 V and 25 mA per Gel. 
Electrophoretic separation was performed until the samples had almost reached the bottom of the 
gel and the marker (PageRuler Prestained Protein Ladder, Fermentas) bands were separated 
sufficiently.  
Gels were removed from the cassettes and the separated proteins transferred to a nitrocellulose 
membrane (Amersham, GE Healthcare, Freiburg, Germany) by semi-dry blotting using a custom-
made blotter set to 300 V and 0.8 mA per cm2 of membrane for 1:15 – 1:30 h. To eliminate unspecific 
binding of antibodies, the membrane was blocked in 5% skim milk powder in TBST for at least one 
hour at room temperature with gentle agitation. Primary antibodies were diluted at an antibody-
dependent concentration (Table 2-3) in either 5% skim milk powder or BSA in TBST and incubated 
under gentle agitation either over night at 4°C or for one hour at room temperature. Following 
incubation with the primary antibody, membranes were washed 3 times in TBST and the HRP-
conjugated secondary antibody, diluted in 5% skim milk in TBST, was incubated for 30 minutes to 2 
hours at room temperature with gentle agitation. To visualise protein bands, membranes were 
washed 3 times in TBST and subjected to a chemiluminescent substrate (CheLuminate-HRP 
PicoDetect, or SuperSignal West Femto Chemiluminescent Substrate). Luminescence was detected 
with a Digital CCD Camera and analysed with Wasabi imaging software (Hamamatsu Photonics, 
Herrsching am Ammersee, Germany).  
If re-probing was desired, membranes were incubated with stripping buffer for 10 – 30 minutes, 
washed three times and blocked with 5% skim milk in TBST for one hour before primary and 
secondary antibodies were added as described above. 
4x Loading Buffer 
Tris, pH 6.8 250 mM 
SDS 8% 
Glycerol 40% 
ß-Mercaptoethanol 400 mM 
Bromophenol blue 0.02% 
 
 
Electrophoresis running buffer 
Tris 124 mM 
Glycerol 960 mM 
SDS 0.5% 
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TBST 
Tris 50 mM 
NaCl 150 mM 
Tween 20 0.1% 
 
6x Loading Buffer 
Tris, pH 6.8 375 mM 
SDS 9% 
Glycerol 50 % 
ß-Mercaptoethanol 9% 
Bromophenol blue 0.03% 
Transfer buffer 
Tris 48 mM 
Glycerol 39 mM 
SDS 0.037% 
Methanol 10 % 
Stripping buffer 
Glycerol 0.2 M 
NaCl 0.5 M 
pH 2.8  
 
 
 
Table 2-3: Primary Antibodies for Western Blotting 
Antigen MW 
(kDa) 
Isotype Dilution Provider, Cat. # 
ß-Actin 42 Rabbit polyclonal IgG 1:1000 in 5% 
BSA 
Sigma-Aldrich A2066 
BiP 78 Rabbit monoclonal IgG 1:1000 in 5% 
BSA 
Cell Signaling Technology 
#3177 
GAPDH 36 Mouse monoclonal 
IgG1 
1:10000 in 5% 
BSA  
Chemicon MAB374 
IRE1α 130 Rabbit monoclonal IgG 1:500 in 5% BSA Cell Signaling Technology 
#3294 
Nitrotyrosine  Mouse monoclonal 
IgG2b 
 Abcam ab7048 
Txnrd2 
(#1C4) 
56 rat monoclonal 1:1 in 5% BSA custom 
PDI 57 Rabbit monoclonal IgG 1:1000 in 5% 
BSA 
Cell Signaling Technology 
#3501 
PHD-2 50 Rabbit monoclonal IgG 1:500 in 5% BSA Cell Signaling Technology 
#4835 
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Secondary Antibodies for Western Blotting 
Antigen Dilution Provider, Cat. # 
Goat anti-mouse IgG HRP 
conjugate 
1:5000 in 5% skim milk Calbiochem 401253 
Goat anti-rabbit IgG HRP 
conjugate 
1:2000 in 5% skim milk Calbiochem 401353 
Goat anti-rat IgG HRP conjugate 1:10000 in 5% skim 
milk 
Jackson ImmunoResearch 112-035-
062 
 
2.9 Polymerase Chain Reaction 
2.9.1 Isolation of mRNA 
To investigate the regulation of a range of genes, total mRNA was isolated from cells using the 
RNeasy Mini Kit (Qiagen). For cell lysis, 106 cells were incubated with a cell number-appropriate 
amount of RLT buffer supplemented with ß-Mercaptoethanol. RLT buffer disrupts cells based on the 
denaturing capacity of its constituent guanidine-thiocyanate while ß-Mercaptoethanol additionally 
inactivates RNAses. Following cell lysis, samples were further homogenised with QIAshredder 
columns (Qiagen) to remove insoluble material and reduce sample viscosity. Subsequently, Ethanol 
was added to each sample to improve binding conditions and passed through RNEasy Mini Spin 
columns (Qiagen). The columns were centrifuged at 10,000 x g during which the RNA precipitates and 
binds to the silica-based membrane in the columns and contaminants are removed. Finally, RNA was 
eluted in RNase-free water and aliquots stored at -20°C after the concentration of RNA (260/280 nm) 
was measured with a spectrophotometer (Eppendorf, Hamburg, Germany). 
2.9.2 Synthesis of cDNA 
To reverse transcribe mRNA to cDNA, a Reverse Transcription Kit (Promega) was used. First, 1 µg of 
RNA diluted in 5 µl dH2O was incubated with Oligo(dT) primers at 65°C for 7 minutes. Subsequently, 
the remaining constituents of the Kit were added to a total volume of 10 µl and incubated for 1 hour 
at 37°C. Enzyme activity was halted by increasing the temperature to 97°C for 7 minutes before the 
mixture was diluted 1:10 with dH2O. cDNA was then either stored at -20°C or used directly for semi-
quantitative PCR.  
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2.9.3 Polymerase Chain Reaction (PCR) 
Polymerase Chain Reaction was performed in either a Mastercycler ep gradient S (Eppendorf) or a 
PTC-100 Programmable Thermal Controller (MJ research Inc., St Bruno (Quebec), Canada) following 
the general outline listed in Table 2-4. Individual steps were adjusted according to primer and/or 
sample determinants. Primers were designed online (Primer3, v. 0.4.0) and, if possible, the sequence 
confirmed by electronic PCR (http://www.ncbi.nlm.nih.gov/sutils/e-pcr/reverse.cgi). All primers were 
obtained from Eurofins MWG GmbH (Ebersberg, Germany) Sample cDNA was added to a mixture 
containing an equal volume of primers, 10x PCR Buffer, DMSO, dNTPs, Taq Polymerase and dH2O to a 
total volume of 20 µl. Following PCR amplification, product size was determined by gel 
electrophoresis. 
Table 2-4: Model PCR protocol 
Step Time Temperature Cycles 
Initial denaturation 3 min 94°C  
Denaturation 1 min 94°C  
Annealing 1 min 55 -65°C, according to primer pairs 30 - 35 
Elongation 1 min 72°C  
Prolonged elongation 7 min 72°C  
 
2.9.4 Agarose Gel Electrophoresis 
Agarose gels with concentrations ranging from 1% to 2.3% were prepared in TAE buffer and Gel Red 
(0.04 µl/ml) added. Once the gel had polymerized a DNA ladder (25-2010, Peqlab) and samples, 
prepared with loading buffer (Coral Load Buffer 10x, Qiagen) were applied to the gel pockets. 
Electrophoresis was performed within a gel chamber (Peqlab) powered at 150 Volts/500 mA (Phero-
Stab 0310, Biotec-Fischer, Reiskirchen, Germany) and product fluorescence detected with a Gel Doc 
1000 station (Bio-Rad, Munich, Germany). 
TAE Buffer (50x) 
Tris 2 M 
Acetic Acid 1 M 
EDTA 50 mM 
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2.10 Flow Cytometry 
Flow cytometry is a widely employed method to analyse cells and can be applied to investigate cell 
number, shape, size, and granularity as well as cell surface and cytosolic expression of proteins using 
fluorescent antibodies. Furthermore, the fluorescent properties of a range of reagents allow flow 
cytometry to be used to detect changes such as in electric potentials and the production of reactive 
oxygen species. 
A flow cytometer generally consists of a fluidics unit, an optical system and respective electronics as 
well as a computer to control the system and for visualisation. In principle, single cells are 
transported via a sheath of fluid and delivered to a laser source. The laser light is scattered as it 
passes through the cell and the scattering of the light is collected by specifically positioned detectors. 
The direction of scattered light can give an estimation of cell size (forward scatter, FSC) and 
granularity, e.g. number of vacuoles or organelles, (side scatter, SSC) of a cell. In addition to cell 
morphology, different lasers can also be employed to excite certain fluorescent antibodies or 
reagents. Corresponding detectors can then be used to quantify cell surface or cytosolic proteins as 
well as cellular markers, e.g. of cell cycling or health.   
2.10.1 Quantification of reactive oxygen species 
eEPCs were cultured as described above without ß-Mercaptoethanol. After four days, 106 cells were 
allowed to grow in gelatine-coated 6-well plates overnight at standard culture conditions without ß-
Mercaptoethanol. Subsequently, the medium was exchanged with Medium supplemented with 5 µM 
of the cell-permeable redox-sensitive fluorogenic dye, CellROX (Invitrogen, Life Technologies) and 
incubated for 30 minutes at 37°C. Cells were then washed with PBS three times, detached with 
trypsin, centrifuged for five minutes at 1200 RPM and resuspended in 500 µl PBS. CellROX 
fluorescence (excitation 644nm, emission 665 nm; principal depicted in Figure 2-2) was then 
measured by flow cytometry (FL-6) using a Gallios 2/8 flow cytometer (Becton Coulter. Krefeld, 
Germany). Fluorescence results were divided by the values of isotype controls to correct for 
autofluorescence. 
 
       Reduced, non-fluorescent            Oxidised, fluorescent 
 
Figure 2-2: Mechanism of CellROX redox-sensitivity  (Image courtesy of Life Technologies) 
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2.10.2 Measurement of mitochondrial membrane potential  
To measure the mitochondrial membrane potential, eEPCs were cultured and pre-treated without ß-
Mercaptoethanol as described for the CellROX measurement. Cells were trypsinised, centrifuged 
(200 rcf, five minutes) and 106 cells resuspended in warm PBS. Subsequently, cells were incubated 
with 2 µM of the MitoProbe™ JC-1 Assay Kit (Invitrogen, Life Technologies; chemical structure 
outlined in Figure 2-3) for 30 minutes in an incubator set to 37°C and 5% CO2, according to the 
manufacturer’s protocol. Like CellROX, JC-1 (5’,6,6’-tetrachloro-1,1’,3,3’-
tetraethylbenzimidazolylcarbocyanine iodide) is a cell-permeable dye. It specifically localises to the 
intermembrane space of mitochondria and, when excited at 488 nm, fluoresces at either of two 
membrane potential-dependent wave lengths. At physiological membrane potentials (approximately 
-180 to -220 mV) red-fluorescent J-aggregates form which can be detected at 590 nm. As the 
potential becomes more positive, J-aggregates dissociate and the green fluorescence of J-monomers 
can be detected at 529 nm. Prior incubation with the membrane potential disruptor CCCP (carbonyl 
cyanide 3-chlorophenylhydrazone) for five minutes at 37°C served as a positive control. 
Subsequently, cells were washed twice by centrifugation (200 rcf, five minutes) and resuspended in 
warm PBS before the shift of fluorescence from green to red was measured by flow cytometry. 
 
Figure 2-3: Chemical structure of the mitochondrial membrane potential marker JC-1  (image 
courtesy of Life Technologies) 
 
2.11 Statistics 
For statistical comparison of results, experiments were conducted at least three times. Results were 
compiled using Excel (Microsoft) and analysed using the statistical software SigmaPlot v. 11.0 (Systat 
Software, Erkrath, Germany). Statistical comparison of two groups for normally-distributed data was 
achieved by Student’s t-test or by Rank Sum test if the data was not distributed normally. For the 
comparison of multiple groups, 2-way analysis of variance (ANOVA) followed by a Holm-Sidak Post-
Hoc test was performed. The corresponding tests are indicated in the figure legends. In all statistical 
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tests, a p-value < 0.05 was considered statistically significant and data is presented as  
mean ± standard error of the mean (SEM) (normal distribution) or median and interquartile  
range (25 – 75 %) for non-normal distribution of data. If data was excluded, only data points three 
standard deviations (SD) above the mean were eliminated. 
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3 Results  
 
3.1 Txnrd2 deletion affects cellular redox state and mitochondrial health 
To assess the impact of Txnrd2 deletion in vitro, we used Txnrd2-deficient eEPCs as substitutes for 
ECs. Since the eEPCs had been previously isolated from embryos of Txnrd2-heterozygous mice, the 
protein level of Txnrd2 was confirmed in each clone by western blot. A representative blot 
confirming the lack of Txnrd2 in eEPC protein lysates is displayed in Figure 3-1 (A). Whether the 
deletion of Txnrd2 impacts on the cellular concentrations of ROS and ΔΨm was assessed after 
culturing the cells in medium lacking ß-Mercaptoethanol for four days followed by seeding of 1x106 
cells/well in 6-Well plates over night. The following day, ROS and ΔΨm were assessed by flow 
cytometry using respective markers. 
3.1.1 Txnrd2 deletion increases ROS in eEPCs in vitro 
To investigate how the deletion of Txnrd2 impacts on cellular levels of ROS, eEPCs were incubated 
with the Redox-sensitive dye CellROX and fluorescence intensity measured by flow cytometry. As 
displayed in Figure 3-1 (B), Txnrd2 deletion resulted in a significant increase in the fluorescence 
intensity (FL6) of CellROX (Txnrd2+/+: 17.002; Txnrd2-/-: 23.382 (median); p < 0.001, Rank-Sum test), 
representative of increased cellular ROS concentrations in Txnrd2-/- eEPCs.  
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Figure 3-1: Txnrd2 deletion increases ROS levels in eEPCs. (A) Representative western blot displaying the 
absence of Txnrd2 in eEPCs. β-actin served as loading control. (B) The fluorescence of the redox-sensitive dye 
CellROX was measured by flow cytometry and the values corrected for autofluorescence using the values 
obtained from isotype controls not containing the dye. Dots indicate outliers, solid lines represent the median 
values and dotted lines the mean. * p < 0.001, Rank-Sum Test, n =.50 (Txnrd2 
+/+
) – 51 (Txnrd2 
-/-
). 
 
3.2 Txnrd2 deletion impairs mitochondrial membrane potential in eEPCs 
in vitro 
Since the eEPCs lacking Txnrd2 were subject to increased ROS levels and the mitochondrial Txn 
system is considered to be involved in the most important H2O2 detoxification processes, we sought 
to investigate whether this increased mitochondrial ROS burden may also affect the ΔΨm in these 
cells. Indeed, as depicted in Figure 3-2, eEPCs lacking Txnrd2 exhibited a significantly impaired 
potential of their mitochondrial membranes, indicative of impaired mitochondrial health  
(Txnrd2+/+: 1.03±0.048; Txnrd2-/-: 0.85±0.038 (mean ratio±SEM) p < 0.01, t-test). Txnrd2 deletion did 
not lead to complete loss of ΔΨm which is exemplified by incubating the cells with the potential 
disrupter CCCP as a positive control (Txnrd2+/+ CCCP: 0.64±0.012; Txnrd2-/- CCCP: 0.65±0.028). 
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Figure 3-2: Measurement of ΔΨm in eEPCs expressing or lacking Txnrd2. The colour shift in eEPCs 
previously loaded with the cell-permeable, mitochondrial-specific and potential-dependent dye JC-1 was 
assessed by flow cytometry. CCCP was used as a negative control for JC-1. * p < 0.01, t-test, n = 13. 
 
3.3 Effects of endothelial-specific deletion of Txnrd2 in vivo 
The different genotypes of mice employed for the in vivo examination of Txnrd2 deletion in ECs is 
displayed in Figure 3-3 (A). Tamoxifen application resulted in the expected deletion of Txnrd2 in the 
endothelium as exemplarily shown for renal endothelial cells (Figure 3-3 B). Endothelial deletion of 
Txnrd2 had no impact on mouse survival following knockout induction. To investigate the role of 
Txnrd2 in adult ECs under forced angiogenesis as well as arteriogenesis, mice lacking the 
mitochondrial antioxidant specifically in the endothelium were subjected to hind-limb ischemia. By 
ligating the femoral artery in one leg, flow is redirected through pre-existing collateral vessels to 
bypass the occlusion. In the adductor muscle this is suggested to lead to an initial increase in FSS in 
the collateral vessels which is sensed only by ECs. Subsequently, ECs signal this alteration in flow to 
the underlying cells and elicit vasodilatation via the release of NO and H2O2, amongst others. 
Increased FSS, vasodilatation, infiltration of monocytes and other processes then lead to 
arteriogenesis of the collateral vessels. In the calf muscle the upstream obstruction of flow decreases 
O2 availability and thus initiates hypoxic signalling. Hypoxia is a strong initiator of angiogenesis, i.e. 
the sprouting of new capillaries.  
* 
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Figure 3-3: Genotyping of mouse tail clippings and confirmation of Txnrd2 deletion in ECs. (A) 
Various Genotypes of mice as determined by PCR from tail clippings. Only one combination (flox/flox cre
+
) 
represents a Tamoxifen-inducible Txnrd2
ECKO
 mouse. (B) Representative western blot from ECs isolated from 
the kidneys of a Txnrd2
ECWT
 (left) and a Txnrd2
ECKO
 (right) mouse. β-actin served as loading control. 
 
3.3.1 Re-establishment of perfusion in the murine hind-limb 
As displayed in Figure 3-4, values for hind-limb perfusion were calculated as a ratio of the perfusion 
in the sham-operated hind-limb to that in the occluded hind-limb. These ratios were similar between 
wildtype and Txnrd2ECKO mice prior to and immediately after occlusion. Furthermore, no difference 
could be observed after 3 days of recovery. However, after 7 days it became evident that perfusion 
recovery in the occluded hind-limb of Txnrd2ECKO mice was significantly attenuated (0.471±0.0298) 
relative to their wildtype counterparts (0.603±0.0312 (mean±SEM); p < 0.01, 2-Way RM ANOVA and 
Holm-Sidak Post-Hoc test).  
The data presented in Figure 3-4 suggest that the impairment in perfusion in Txnrd2ECKO mice is only 
slight. However, in one Txnrd2ECKO mouse, the perfusion ratio at day 7 hat attained a value close to 
1.00 and this data point was thus revealed as a substantial outlier (three SD above the mean). We 
suspect that the ligation thread or the knot had disintegrated since the occlusion in this mouse was 
successful and perfusion was comparable to other mice at day three. And while a complete recovery 
of perfusion to baseline conditions within seven days is unlikely, we decided not to exclude this data 
point as a) in vivo results naturally tend to spread more than in vitro examinations due to individual 
differences between the animals and b) we could only speculate on the reason for the recovery and 
could not directly identify the cause of the drastic recovery. 
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Figure 3-4: Recovery of perfusion after occlusion of the femoral artery. While no differences in 
perfusion ratio of sham-operated to occluded hind-limb were evident prior to, immediately after and 3 days 
post-surgery in Txnrd2
ECKO
 compared to Txnrd2
ECWT
 mice, recovery was significantly reduced in mice lacking 
Txnrd2 after 7 days. Circles with solid line: Txnrd2
ECWT
; triangles with dashed line: Txnrd2
ECKO
. * p < 0.01, 2-Way 
RM ANOVA and Holm-Sidak Post-Hoc test, n = 11 (Txnrd2
ECWT
) – 12 (Txnrd2
ECKO
). 
 
3.3.2 Assessment of Angiogenesis 
In order to elucidate the cause for the impairment of reperfusion in the Txnrd2ECKO mice after hind-
limb ischemia, we isolated the calf (gastrocnemius) muscles after the final LDI measurement. Ten µm 
thick cryo-sections of the muscle were stained with a primary antibody raised against the EC-specific 
surface protein CD31 coupled to a Cy3-conjugated secondary antibody. Fluorescence microscopy was 
subsequently performed to visualise the capillaries in the calf muscle. Capillary density was evaluated 
as the area fluorescently labelled by the CD31/Cy3 antibody complex relative to the whole area per 
field of view. Within each section photographs were taken at three distinct sites as depicted in  
Figure 3-5. 
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Figure 3-5: Representative images of a gastrocnemius muscle cryo-section. Muscle sections were 
prepared after seven days of hind-limb ischemia. (A) H&E stain of a calf muscle slice from a Txnrd2
ECKO
 mouse. 
Three distinct areas per slice were assessed for capillary density in the CD31/Cy3-labelled sections as indicated 
by the numbered circles. Scale bar: 2 mm. (B) Representative images of fluorescently labelled cryo-sections 
obtained from sham (upper panel) and occluded (lower panel) hind-limbs. CD31/Cy3-labelled ECs are displayed 
in white and the positively stained area evaluated relative to the total field of view. Scale bar: 50 µm. 
 
As illustrated in Figure 3-6 (A), capillary density was significantly lower in the calf muscle of 
Txnrd2ECKO mice than in Txnrd2ECWT mice after seven days of hind-limb ischemia (Txnrd2ECWT: 115.17, 
Txnrd2ECKO: 108.88 (median), p < 0.05, Rank Sum test). Interestingly, this impairment was only 
present in two of the three sites analysed (Figure 3-6 B, Txnrd2ECWT: 134.47; Txnrd2ECKO: 116.18; 
Figure 3-6 C, Txnrd2ECWT: 118.16; Txnrd2ECKO: 108.79 (median), p < 0.05, Rank Sum test). In the third 
area no difference in capillary density was evident between the groups (Txnrd2ECWT: 98.29; 
Txnrd2ECKO: 98.76 (median), p = 0.702, Rank Sum test). In fact, no increase in capillary area fraction 
from the sham-operated limb occurred in this region, possibly due to the development of necrosis in 
this area in both animal groups.  
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Figure 3-6: Evaluation of capillary density in the occluded hind-limb after seven days of ischemia. 
Angiogenesis was evaluated by comparing the increase in capillary area fraction in the calf muscle of the 
occluded hind-limb and expressed as the % difference from the sham-operated calf muscle. (A) There was a 
significantly lower density of capillaries in the calf muscle of Txnrd2
ECKO
 mice when comparing the data from all 
analysed sections together. This significant impairment was present in area 1 (B) and in area 2 (C). (D) No 
difference in the capillary area fraction exists between the two subject groups in area 3. Solid line: median; 
dashed line: mean; Dots: outliers. *p < 0.05; n.s. not significant; Rank Sum Test; n= 8 (Txnrd2
ECWT
) – 9 
(Txnrd2
ECKO
). 
 
3.3.3 Assessment of Arteriogenesis 
While capillary density was indeed attenuated in the occluded hind-limb of Txnrd2ECKO mice, the 
extent the impairment could contribute to the decrease in perfusion measured by LDI is rather small. 
Considering that resistance to flow is inversely proportional to the fourth power of the radius, even 
the sum of all new capillaries would easily be excelled by small diameter changes in the upstream 
collateral vessels of the adductor muscle. We therefore analysed various parameters of remodelling 
in the collateral arterioles of the adductor muscle after seven days of hind-limb ischemia.  
* 
n.s. 
* 
* 
Txnrd2ECWT Txnrd2ECKO Txnrd2ECWT Txnrd2ECKO 
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Five to 6 µm thick paraffin sections of the adductor muscles were H&E stained and both the inner (Ci) 
and outer circumference (Co) of the collateral vessels measured using ImageJ software. From these 
data, vessel wall area (A) and thickness (T) as well as luminal diameter (d) were calculated with the 
following formulas: 
 
 
 
As displayed in Figure 3-7, the collateral arterioles in the occluded hind-limbs were subject to 
substantial remodelling in both the Txnrd2ECWT and Txnrd2ECKO mice seven days post-ischemia. The 
results in Figure 3-8, however, demonstrate that while vessel wall area had increased in both groups, 
this effect was significantly less pronounced in the mice lacking Txnrd2 (Txnrd2ECWT: 686.76 µm2; 
Txnrd2ECKO: 487.28 µm2 (median), p <0.001 Rank Sum test). Interestingly, these mice had a slight but 
significant greater wall area at baseline in the sham hind-limb (Txnrd2ECWT: 180.45 µm2;  
Txnrd2ECKO: 279.71 µm2 (median), p <0.001 Rank Sum test). 
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Figure 3-7: Representative images of thigh muscle paraffin sections. Muscle sections were prepared 
after seven days of hind-limb ischemia and the inner and outer arteriole circumference measured to assess wall 
area, thickness and luminal diameter. A, arteriole; N, nerve; V, venule. Scale bar: 50 µm. 
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Figure 3-8: Assessment of collateral vessel wall area Collateral vessel wall area was greater in Txnrd2ECKO 
mice than in Txnrd2
ECWT
 mice at basal levels. The increase in collateral vessel wall area in the occluded hind-
limb was significantly attenuated in Txnrd2
ECKO
 mice compared to their wildtype counterparts after 7 days of 
hind-limb ischemia. Solid line: median; dashed line: mean; dots: outliers. *p < 0.001; Rank Sum Test; n = 3 
(Txnrd2
ECWT
) – 4 (Txnrd2
ECKO
). 
 
In contrast to the findings on collateral artery wall area, the walls of these vessels were found to be 
similarly thick in Txnrd2ECWT and mice lacking Txnrd2 after seven days of hind-limb ischemia 
(Txnrd2ECWT: 4.22 µm; Txnrd2ECKO: 4.38 µm (median); p = 0.445, Rank Sum test; Figure 3-9 A). 
Analogous to the findings on the wall area, Txnrd2ECKO mice also displayed basally thicker walls in 
their collaterals (Txnrd2ECWT: 2.96 µm; Txnrd2ECKO: 3.79 µm; p <0.001, Rank Sum test). Normalisation 
of the wall thickness of the collaterals in the occluded hind-limb to those in the sham-operated hind-
limb, however, revealed that the increase in thickness above basal levels was significantly attenuated 
in the collateral vessels in the Txnrd2ECKO mice after seven days of hind-limb ischemia  
(Txnrd2ECWT: 134.95 % of sham; Txnrd2ECKO: 106.93 % of sham (median); p < 0.001, Rank Sum test; 
Figure 3-9 B). 
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Figure 3-9: Collateral Vessel Wall Thickness.  (A) At basal levels, collateral vessel wall thickness was 
increased in Txnrd2
ECKO
 mice. After seven days of hind-limb ischemia, wall thickness had increased in the 
occluded hind-limbs of both Txnrd2
ECWT
 and Txnrd2
ECKO
 mice and no difference was evident between the two 
experimental groups. (B) Normalised wall thickness was calculated from the inner and outer circumferences 
and values from the collaterals of the occluded hind-limb normalised to the thickness of the collateral vessels 
of the sham-operated hind-limb. *p <0.001, n.s.: not significant, Rank Sum Test; n = 3 (Txnrd2
ECWT
) – 4 
(Txnrd2
ECKO
). 
 
Finally, since the vascular wall parameters suggested that the remodelling of the collateral vessels in 
the occluded hind-limbs of the Txnrd2ECKO mice were lagging behind those of the Txnrd2ECWT mice, we 
compared the luminal diameters of the collateral vessels. As the previous data already alluded to, the 
lumen of the collateral vessels of the Txnrd2ECKO mice was significantly smaller in diameter as in the 
controls (Txnrd2ECWT: 44.36 µm; Txnrd2ECKO: 37.31 µm (median); p < 0.001, Rank Sum test;  
Figure 3-10). No difference in the luminal diameter of the collateral vessels between Txnrd2ECWT and 
Txnrd2ECKO mice was evident in the sham-operated hind-limb. 
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Figure 3-10: Assessment of luminal diameter in occluded and sham-operated hind-limbs seven days 
after surgery. Following the results obtained on vascular wall area and thickness, luminal diameter was 
significantly smaller in Txnrd2
ECKO
 mice than in Txnrd2
ECWT
 mice. No difference was observed in the sham-
operated hind-limbs. Solid line: median, dotted line: mean; dots: outliers. *p < 0.001; Rank Sum Test; n = 3 
(Txnrd2
ECWT
) – 4 (Txnrd2
ECKO
). 
 
3.4 Possible pathways impaired in angiogenesis and arteriogenesis 
To investigate the cause of the impairment in the remodelling of the collateral vessels in the 
occluded hind-limb of Txnrd2ECKO mice, we assessed flow-mediated dilatation in isolated, 
unremodelled collaterals. This was achieved by increasing the pressure gradient across the vessel. 
Since the hydrostatic outflow pressure from the vessel remained unchanged, the increase in inflow 
pressure changed flow velocity. Unfortunately, no significant difference between Txnrd2ECKO mice 
and their Txnrd2-expressing counterparts was detected (2-Way RM ANOVA and Holm-Sidak Post-Hoc 
test; Figure 3-11). 
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Figure 3-11: Flow-mediated dilatation of unremodelled collateral vessels. No significant difference in 
the vasodilatory response of collaterals from Txnrd2
ECKO
 mice compared to those obtained from Txnrd2
ECWT
 
mice was detected. Circles: Txnrd2
ECWT
; Triangles: Txnrd2
ECKO
; n = 4 (Txnrd2
ECWT
), 9 (Txnrd2
ECKO
); 2-Way RM 
ANOVA and Holm-Sidak Post-Hoc test. 
 
To investigate whether other FSS-independent, endothelium-mediated vasodilatory responses are 
impaired in vessels from Txnrd2ECKO mice, the arterioles employed for the assessment of flow-
mediated dilatation were also assessed for their vasodilatory capacity to Acetylcholine (ACh). As 
displayed in Figure 3-12 (A), collateral arterioles from Txnrd2ECKO mice and their Txnrd2-expressing 
counterparts responded in a similar fashion to increasing concentrations of ACh. 
Concentration-response-curves were also obtained from these vessels in response to the nitric oxide 
donor S-Nitroso-N-acetylpenicillamine (SNAP) to assess the extent of endothelium-independent 
vasodilatation. Similar to the results obtained in response to alterations in flow and ACh, no 
difference in the vasodilatory capacity of collateral arterioles from either Txnrd2ECWT or Txnrd2ECKO 
mice to various concentrations of SNAP were measured (Figure 3-12 B). 
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Figure 3-12: Vasodilation of unremodelled collateral vessels to exogenous vasodilators. (A) The 
vasodilatory responses of collaterals from Txnrd2
ECKO
 mice to increasing doses of ACh were not statistically 
different from those observed in Txnrd2
ECWT
 mice. (B) Similarly, the administration of SNAP did not reveal any 
statistically significant difference in the vasodilatory response of collateral arterioles from Txnrd2
ECWT
 or 
Txnrd2
ECKO
 mice. Circles: Txnrd2
ECWT
, Triangles: Txnrd2
ECKO
; n = 4 (Txnrd2
ECWT
), 9 (Txnrd2
ECKO
); 2-Way RM ANOVA 
and Holm-Sidak Post-Hoc test. 
 
Since the impairment in both angiogenesis as well as arteriogenesis in the Txnrd2ECKO mice should 
have its basis on a disruption of cellular signalling pathways, we investigated those associated with 
defects in these processes. In protein lysates obtained from eEPCs in vitro, western blots for PHD2, a 
protein implicated both in the control of HIF-1α stability as well as in the HIF-1α-independent 
regulation of EC proliferation, were prepared. As displayed in Figure 3-13, PHD2 expression was 
significantly increased at basal levels in Txnrd2-/- eEPCs compared to Txnrd2+/+ eEPCs (Txnrd2+/+: 1.00; 
Txnrd2-/-: 1.27 (median fold expression); p < 0.05, Rank Sum test). 
  
Results 
57 
 
A B 
 
 
 
P
H
D
2
 (
fo
ld
 T
xn
rd
2
+
/+
 e
xp
re
ss
io
n
 le
ve
l)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
 
Figure 3-13: PHD2 expression is increased in Txnrd2-/- eEPCs. Protein lysates from Txnrd2+/+ and Txnrd2-/- 
eEPCs were separated by SDS-Page and immunoblotted for PHD2. Semi-quantitative comparison revealed a 
significant increase in PHD2 protein expression in Txnrd2
-/-
 eEPCs. (A) Representative immunoblot displaying an 
increase in PHD2 expression in Txnrd2
-/-
 eEPCs. (B) Semi-quantitative comparison of PHD2 expression in 
Txnrd2
+/+
 and Txnrd2
-/-
 eEPCs from three western blots. n = 4; *p < 0.05, Rank Sum Test.  
 
Increased ROS levels measured in vitro and the impaired remodelling observed in vivo led us to raise 
the question whether a reduction in NO bioavailability due to the sequestration of the vasodilatory 
gas by O2
-• to form the toxic compound ONOO-. Nitric oxide, O2
-• and ONOO- are difficult to measure, 
so we attempted an indirect measurement of ONOO- damage by assessing the nitration of protein 
tyrosine residues in cell lysates prepared from eEPCs. However, as displayed in Figure 3-14 (A) no 
difference in the nitration of tyrosine residues was evident at baseline conditions between Txnrd2+/+ 
and Txnrd2-/- eEPCs. Since ECs subjected to increased FSS in vivo would augment their NO production 
to elicit flow-mediated dilatation, we also assessed whether the administration of 10 µM sodium 
nitroprusside (SNAP), a NO donor, may increase protein nitrotyrosine. Again, no effect was evident in 
Txnrd2-/- eEPCs compared to their Txnrd2-expressing counterparts (Figure 3-14 B).  
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Figure 3-14: Tyrosine nitration in eEPCs.  Nitration of tyrosine residues in proteins was assessed by 
immunoblot using an anti-nitrotyrosine antibody. (A) No difference the nitration of tyrosine residues of 
proteins was evident between Txnrd2
+/+
 and Txnrd2
-/-
 eEPCs. (B) To assess whether increased presence of NO 
would lead to an increase in the nitration of protein tyrosine residues, SNAP was administered to eEPCs prior to 
collecting the cell lysate. Again, no difference was observed between Txnrd2
+/+
 and Txnrd2
-/-
 eEPCs. 
 
3.5 Additional consequences of Txnrd2 deletion  
As the mitochondria can affect the function of the ER, for example by altering the Ca2+ resupply via 
the Na+/Ca2+ exchanger, we were intrigued to find increased levels of the ER resident proteins 
Binding immunoglobulin Protein (BiP) and Protein Disulfide Isomerase (PDI), typically associated with 
ER stress (Figure 3-15) in Txnrd2-deficient eEPCs.  
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Figure 3-15: Txnrd2 deletion leads to increased levels of ER stress proteins. (A) Protein expression 
levels of BiP were assessed by immunoblot (upper panel). Semi-quantitative analysis of four western blots 
revealed a significant upregulation of BiP protein expression in Txnrd2
-/-
 eEPCs  
(*p < 0.05, Rank Sum Test; lower panel). (B) PDI protein expression was also assessed by immunoblot (upper 
panel). Analogous to BiP, semi-quantitative analysis of five western blots confirmed a significant increase of PDI 
on the protein level in Txnrd2
-/-
 eEPCs (*p < 0.05, Rank Sum Test; lower panel). 
 
PDI can be released from ECs and has been implicated in the commencement of the coagulation 
cascade, possibly by activating tissue factor 122. Thus, the finding on increased PDI protein levels in 
Txnrd2ECKO mice led us to re-examine the paraffin sections of the collateral vessels in the adductor 
muscles. Indeed, in two of the four Txnrd2ECKO mice from which paraffin sections had been prepared 
we found white thrombi in the collateral vessels and in the femoral artery (Figure 3-16). 
Furthermore, in paraffin sections stained for haematoxylin and the leukocyte marker CD45, we found 
atherosclerotic-like depositions in the femoral artery of a third Txnrd2ECKO mouse (Figure 3-17). 
Neither thrombi nor atherosclerotic-like lesions were evident in the paraffin sections prepared from 
any of the three Txnrd2ECWT mice.  
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Figure 3-16: Depositions in the collateral arterioles and femoral artery of Txnrd2ECKO mice. (Top 
panel) White thrombus-like depositions were found in the collateral arterioles of Txnrd2
ECKO
 mice from the 
hind-limb ischemia experiments. The blood-filled structure to the left of the arteriole is a corresponding venule 
and the nerve is displayed in the upper right corner of the image. Scale bar 20 µm. (Lower panel) Thrombotic 
depositions in the wall of the sham-operated femoral artery of a Txnrd2
ECKO
 mouse. Scale bar 50 µm (left), 20 
µm (right).  
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Figure 3-17: CD45-positive staining in femoral artery of Txnrd2ECKO mouse. In the occluded femoral 
artery of a Txnrd2
ECKO
 mouse we found atherosclerotic-like depositions which were also positively stained for 
the leukocyte marker CD45 (red, indicated by arrows). Scale bar 50 µm. 
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4 Discussion 
The precise regulation of cellular redox status is vital in controlling processes such as cellular 
proliferation or growth inhibition, and cellular activation or death 92, 123, 124. The Txn system has been 
identified as one of the major regulators of cellular redox state and as such has begun to receive 
increasing interest 125. As a result, the Txn system is now known to participate in the control of 
cellular function, proliferation, and redox-dependent signalling processes in addition to its 
antioxidative effects 23. Txnrd1, for instance, is being considered as a target for anti-cancer 
therapeutics due to its effects on proliferation of tumour cells 126, 127. Physiologically, Txnrd1 is 
relevant not only as an antioxidant but also, due to its wide substrate profile, in the regulation of 
cellular processes ranging from signalling pathways to the induction of apoptosis 36, 128. In contrast to 
Txnrd1, however, the role of the mitochondrial thioredoxin reductase is still largely obscure.  
In a previous study, an essential role in development could be ascribed to Txnrd2: a lack of the 
enzyme substantially impaired embryogenesis, and led to incomplete heart development and 
function as well as considerable defects in haematopoiesis 38. Furthermore, we and others have 
shown that Txnrd2 can affect cellular proliferation and mitochondrial integrity as well as ROS levels in 
vitro, and can influence tumour growth and the angiogenic switch in vivo 37, 116, 129, 130. The emergence 
of inducible, cell-specific knockout mice now circumvents the limitation of embryonic lethality in 
mice with a ubiquitous deletion of Txnrd2. Thus, a recent study which employed an inducible, 
cardiomyocyte-specific Txnrd2 deletion mouse has advanced our understanding on the role Txnrd2 
plays in the progression of heart failure 39.  
With a similar mouse in which the inducible deletion of Txnrd2 is under the control of the VE-
cadherin promoter, we endeavoured to define the role of Txnrd2 specifically in the endothelium. 
Hind-limb ischemia in these mice allowed us to examine the in vivo effect of endothelial Txnrd2 
ablation on angiogenesis and arteriogenesis, vascular processes both critically dependent on a 
functional endothelium. Since dysfunctional ECs are also implicated in several vascular diseases such 
as atherosclerosis, we also explored other phenotypical characteristics in these mice. Furthermore, 
with the use of eEPCs lacking Txnrd2, employed as substitutes due to the limited availability of adult 
ECs, we performed in vitro experiments to analyse the impact of Txnrd2 deletion on cellular ROS 
levels, mitochondrial integrity and potentially affected signalling pathways. 
Indeed, we could show that Txnrd2 deletion leads to an increase in cellular ROS levels and impairs 
ΔΨm in eEPCs. In the living organism, EC-specific deletion of Txnrd2 significantly attenuated both 
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vascular remodelling processes investigated and our findings insinuate that these mice are prone to 
develop vascular wall depositions. 
 
4.1 Txnrd2 deletion increases cellular ROS levels 
Several well-known sources of radicals may contribute to the elevated levels of ROS observed in the 
Txnrd2-/- eEPCs. While the mitochondrial electron transport chain (ETC) is a substantial site of ROS 
production in many cell types including ECs, the roles of other sources are frequently reported. 
Especially the NAD(P)H oxidases have received increased attention and it is now well established that 
ECs are equipped with specific NAD(P)H oxidase isoforms, including the membrane-associated Nox2-
containing subtype, which produces mainly O2
-•, and Nox4, which primarily generates H2O2 
131-133. 
However, ECs are also equipped with the Nox1 and Nox5 isoforms as well as other enzymes that 
contribute to the overall cytosolic levels of ROS, such as the xanthine-dependent system which 
consists of xanthine dehydrogenase, xanthine oxidoreductase and xanthine oxidase, capable of 
producing both O2
-• and H2O2 
134, 135. Finally, oxidation of tetrahydrobiopterin (BH4), a cofactor for 
NOS, shifts the main product of NOS from NO to O2
-• which, especially in the vasculature with its 
dependence on NO-mediated vasodilatation, can have detrimental effects 135, 136. In order to balance 
the production of radicals from these sources, cells are equipped with a variety of enzymatic ROS 
detoxification systems, including the Txnrd2/Txn2/Prx3 axis which, together with glutathione, is 
considered the main line of defence in the maintenance of physiologic levels of mitochondrial  
H2O2 
115, 137. Considering that the mitochondrial thioredoxin system can detoxify more than 60% of 
this organelle’s total H2O2 production, it is not surprising that an increasing number of studies report 
a strong effect of impaired Txnrd2 activity on cellular H2O2 levels 
138. For example, the anti-
rheumatoid and anti-cancer gold(I) compound, auranofin, a potent inhibitor of Txnrd2 enzymatic 
activity at low concentrations, has been shown to prevent Txn2 redox cycling, to increase the 
oxidation of Prx3, and lead to a significant increase in H2O2 emission from isolated mitochondria 
139. 
In line with these findings and previous examinations in our laboratory with mouse embryonic 
fibroblasts (MEFs) lacking the enzyme, we also measured a significant increase in ROS levels in 
Txnrd2-/- eEPCs. While the compound we used to detect ROS, CellROX, is unspecific for the exact 
nature of oxidants, an earlier study using H2O2-specific boronate-based fluorophores confirmed that 
the ablation of Txnrd2 in MEFs leads to an accumulation of H2O2 in the mitochondria and cytosol of 
these cells 116. Data from this study also suggests that the increased accumulation of H2O2 is due to 
reduced detoxification rather than an increased mitochondrial production of this ROS as the 
expression of Prx3, which receives reducing equivalents from Txnrd2 via Trx2, is significantly 
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augmented in Txnrd2-deficient MEFs, an effect which is frequently observed in response to 
exogenous administration of H2O2 
116. Considering that the eEPCs employed in this study are also 
impaired with regard to the Txnrd2/Txn2/Prx3 axis, it is likely that the increased levels of ROS we 
report here may reflect mainly an increased presence of H2O2; however, the contribution of the 
short-lived radical O2
-• or other oxygen radicals to the measured ROS levels cannot be excluded using 
this general ROS sensor. 
While the majority of H2O2 detoxification may occur via this process with only an indirect 
involvement of Txnrd2, a direct utilisation of H2O2 by Thioredoxin reductases, due to their broad 
substrate profile, has also been discussed. According to Zhong and Holmgren, the C-terminal Sec-
containing active site in Txnrd1 could directly reduce H2O2, albeit at relatively high concentrations of 
the enzyme 140. Considering the strong sequence homology between the different Txnrd isoforms 
and that particularly the Sec incorporation in the C-terminal active site is highly conserved between 
all Txnrds, it may well be that this affinity for H2O2 may also apply to Txnrd2, thereby adding another 
avenue for H2O2 accumulation in the Txnrd2
-/- eEPCs employed in this study.  
Extrapolating the reports in the literature, previous studies from our laboratory and the findings on 
elevated levels of ROS in eEPCs to the endothelium and taking into account that mitochondria in ECs 
are not the main site responsible for energy production – the main pathway in the synthesis of ATP is 
by anaerobic glycolysis – one must raise the question what an imbalance of mitochondrial-derived 
ROS may elicit in these cells 108. Possibly, the impact of impaired H2O2 detoxification by the lack of 
Txnrd2 may be exacerbated by a “vicious circle“ of oxidative damage resulting in increased 
production of additional ROS and subsequent exacerbation of oxidative stress 141, 142. Taking this and 
the above mentioned variety of ROS sources into account as well as the recent suggestion that the 
main task of EC mitochondria and mitochondrial-derived ROS is the participation in cellular signalling 
events, for example by modifying, amongst others, Ca2+ dynamics, impaired control of mitochondrial 
ROS production and release, including the longer lived and lipid soluble radical H2O2, could restrict 
the signalling efficiency within a cell 110. For example, ROS have been described to impact on 
angiogenesis by altering the activity of PHD2 via the oxidation of the cofactor Fe2+, leading to HIF-1α 
stabilisation in response to hypoxia 84. Additionally, an increase in ROS can activate a number of 
transcription factors, including NFκB and AP-1, leading to the expression of VEGF and favouring 
angiogenesis 74, 75. The regulation of these pathways, however, pertains to cells with an otherwise 
normal redox status and possibly not to ECs experiencing basally elevated ROS.  
In regard to the response of vessels to alterations in blood flow characteristics, changes in FSS induce 
the release of O2
-• and H2O2 from the endothelium 
58, 93, 143. Basally elevated ROS could thus also 
interfere with the ROS-dependent signalling of FSS, especially taking into account that during 
exposure to FSS EC-derived H2O2 can act upon the underlying VSMC layer 
94. In addition, high 
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concentrations of H2O2 have also been shown to inhibit the activity of MMP-2 which could possibly 
interfere with outward remodelling of blood vessels 98. Conditions with elevated ROS in the 
vasculature such as hypertension, diabetes, inflammation and aging suggest that a functional 
antioxidant defence is of substantial importance in the endothelium and our data implies the 
necessity of mitochondrial thioredoxin reductase in endothelial redox homeostasis.  
At this stage one can only speculate whether and how the elevated concentrations of ROS measured 
in the Txnrd2-deficient eEPCs employed in this study lead to an impairment of signalling processes, in 
particular without having identified a precise signalling cascade for further investigation. And while 
we cannot directly measure levels of ROS in the Txnrd2-deficient endothelium, these data, together 
with the previous findings in other cell types described above, do suggest, however, that the ECs of 
Txnrd2ECKO mice bear an increased oxidative burden which may serve as the underlying cause for the 
subsequently discussed results. 
 
4.2 Mitochondrial membrane potential is altered in Txnrd2-/- eEPCs. 
Since the eEPCs employed in this study lack a major line of defence against mitochondrial H2O2 and 
as H2O2 has been shown to dissipate ΔΨm in a variety of cells, we investigated the effect Txnrd2 
deletion in eEPCs on this transmembrane potential 114, 144. Using a cell-permeable dye that locates 
specifically to the mitochondrial intermembrane space where its aggregation status-dependent 
fluorescence wavelength changes with the membrane potential, we measured a significant reduction 
of ΔΨm in Txnrd2-/- eEPCs 145. Using the membrane potential disruptor CCCP as a positive control we 
could also observe that the potential was not completely lost. A complete dissipation of ΔΨm would 
result in the remodelling of the mitochondrial cristae, matrix condensation, the release of 
cytochrome C into the cytosol, and ultimately in apoptotic cell death which we did not observe 146. In 
contrast, the eEPCs lacking Txnrd2-/- in our study displayed no apparent differences in proliferation or 
viability as would be the case for an enhanced rate of apoptosis in these cells.  
While our results do not enable the determination of the exact reason for the reduction of ΔΨm, it 
has been described that its maintenance requires sufficient oxidisable substrates for the ETC, O2, and 
a physiological cytosolic pH, amongst others 146. It is therefore possible that the elevated levels of 
H2O2 in Txnrd2
-/- eEPCs affected any of these determinants. Alternatively, ΔΨm dissipation may result 
from dysfunctional ETC complexes. H2O2 can react with transition metals to yield the highly toxic and 
DNA-damaging hydroxyl radical (HO•) via the Fenton reaction (Fe2+ + H2O2 ↔ Fe
3+ + OH + HO•). 
HO•-induced damage to mitochondrial DNA which is transcribed to form the ETC complex proteins 
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may result in the transcription and expression of defective variants of these proteins, possibly 
resulting in the impairment of ΔΨm 147.  
Dissipation of ΔΨm could result in a variety of consequences, the significance of which could not be 
assessed but may contribute to an additional functional impairment of the eEPCs lacking Txnrd2 in 
their mitochondria: molecular transport, including that of proteins and cations such as K+ and Ca2+ 
into and out of the mitochondria requires an intact ΔΨm. Furthermore, the removal of cations from 
the mitochondrial matrix, e.g. via the Na+/Ca2+ exchanger and the K+/H+ antiporter is also ΔΨm-
dependent 110, 148. Failure to correctly regulate the net movement of cations can lead to the influx of 
cytosolic water and subsequent mitochondrial swelling which can further hinder mitochondrial  
traffic 149. Mitochondrial swelling may then affect both the function of this organelle as well as the 
entire cell. Thus, an increase in mitochondrial matrix volume can increase ATP production by 
activating the ETC, a process during which additional ROS are produced, resulting in a vicious  
circle 149. Additionally, the increased space required by the swollen mitochondria may also impose 
mechanical constraints on other cellular structures 150. Mitochondrial swelling has thus been shown 
to cause abnormal mitochondrial fusion in fibroblasts and cardiomyoblasts, resulting in a donut-
shaped mitochondrial morphology. This abnormal morphology has also been demonstrated in 
mitochondria of human umbilical vein endothelial cells (HUVECs) and could explain the decrease in 
motility and deregulation of fusion and fission following the dissipation of ΔΨm 142. Whether 
mitochondrial swelling also occurs in eEPCs or ECs lacking Txnrd2 will be investigated by transmission 
electron microscopy in future studies. 
While the findings in eEPCs on ΔΨm serve as an indicative marker for mitochondrial function, we 
cannot conclude from this data alone how severe this may impact on the Txnrd2-deficient 
endothelial cells. However, the dissipation of ΔΨm in the eEPCs lacking Txnrd2 illustrates that the 
deletion of Txnrd2 results not only in increased ROS levels but that mitochondrial and thus also 
cellular integrity and function may also be affected. This is of particular importance when considering 
that impairments in mitochondrial and cellular integrity could potentially contribute to a variety of 
vascular diseases in which endothelial dysfunction is implicated, such as atherosclerosis, diabetes 
and ischemia/reperfusion injury. 
 
4.3 A lack of endothelial Txnrd2 impairs vascular remodelling in vivo. 
The in vitro results on the production of ROS and the dissipation of ΔΨm in eEPCs lacking Txnrd2 
suggest that substantial impairments in the functionality of ECs in Txnrd2ECKO mice may also exist in 
vivo. We attempted to investigate the impact of Txnrd2 deletion in the endothelium on vascular 
remodelling processes by employing a model of ischemia- and hypoxia-induced remodelling in the 
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murine hind-limb. Both hypoxia and ischemia initiate compensatory, endothelium-dependent 
vascular remodelling processes, albeit by different mechanisms. While the lack of oxygen during  
hypoxia leads to angiogenesis in the calf muscle via increased HIF-1α stability and VEGF release, the 
altered haemodynamics following ischemic occlusion of the femoral artery initiate signalling 
pathways, including in the endothelium, in the non-ischemic pre-existing collateral vessels of the 
thigh muscle, leading to arteriogenesis 151. 
Angiogenesis, the sprouting of new capillaries from an existing network, occurs in response to a lack 
of oxygen causing the inactivation of PHD2 and subsequent stabilisation of HIF-1α. The sensitivity of 
both PHD2 inactivation and HIF-1α stabilisation to ROS in hypoxic angiogenesis has frequently been 
reported 84, 152-155. Likewise, the participation of ROS in FSS-dependent vasodilatation, activation of 
growth factors and infiltration of pro-arteriogenic monocytes, all processes governing arteriogenesis, 
i.e. the remodelling of existing arterioles in response to altered haemodynamics, have also been 
described 35, 58-60, 76, 80, 93, 95, 143. Indeed, using LDI we could show that the perfusion recovery after 
occlusion of the femoral artery in Txnrd2ECKO mice was significantly reduced compared to Txnrd2ECWT 
mice after seven days, suggesting that either angiogenesis or arteriogenesis, or both could be 
impaired.  
In response to ischemia, ROS levels have been reported to increase in the area in which the collateral 
arterioles undergo arteriogenesis, as well as in the hypoxic calf muscle 20, 132. As long as this increase 
does not exceed the antioxidant defence capacity of the affected cells it is likely that the ROS partake 
in the ischemia-associated signalling and growth processes. However, when ROS are already basally 
elevated as in the Txnrd2ECKO mice used in this study, the additional ischemia-induced increase may 
result in levels of ROS that impair the vascular compensation of ischemia. In support, in a study in 
which mice were exposed to cigarette smoke equivalent to levels experienced by heavy smokers and 
sufficient to elicit oxidative stress, LDI measurements revealed a significantly impaired recovery from 
ischemia 132. Correspondingly, blocking ROS production or increasing the cellular antioxidative 
capacity has been shown to exert beneficial effects on the re-establishment of perfusion in response 
to ischemia. In the study in which mice were exposed to cigarette smoke, for instance, it was shown 
that recovery of blood flow and neovascularisation seven days after hind-limb ischemia was greater 
in transgenic mice lacking Nox2, a subunit of the ROS producing enzyme NADPH oxidase, compared 
to wildtype mice, both when exposed to smoke as well as under control conditions 132. In support for 
the involvement of mitochondrial-derived ROS in the vascular response to hind-limb ischemia, the 
transgenic overexpression of Txn2 in ECs has also been shown to augment perfusion recovery via 
both arteriogenesis and angiogenesis as early as three days post-surgery 20. Possibly the opposite 
holds true in the present study – a defective redox cycling of Txn2 due to the lack of Txnrd2 impairs 
reperfusion.  
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The beneficial effects of an increased antioxidative capacity can also be achieved by exogenous 
antioxidants or compounds that reverse ROS-induced damage such as the reduction in NO 
bioavailability. Thus, the administration of Vitamin C, BH4 and L-Arginine in the chow of mice prior to 
and during hind-limb ischemia significantly improved long-term recovery compared to mice receiving 
standard diet 156. Despite the signalling roles ascribed to ROS in response to hind-limb ischemia, 
these data suggest that low basal levels of radicals provide a better foundation for vascular 
remodelling and that the boundary between signalling concentrations of ROS and toxic levels is 
narrow. A basal overabundance of vascular ROS, as is the case in the Txnrd2ECKO mice, is thus even 
more likely to impair the recovery of perfusion. 
4.3.1 Angiogenesis 
Since the model of hind-limb ischemia employed in this study allows the analysis of both 
arteriogenesis and angiogenesis in the normoxic thigh and the hypoxic calf muscle of the same 
mouse, we analysed these muscles seven days after the ligation of the femoral artery to assess 
typical parameters of these adaptive processes.  
In the calf muscle we found a significant reduction in the angiogenic response in Txnrd2ECKO mice 
compared to their Txnrd2-expressing counterparts seven days after the occlusion of the femoral 
artery as assessed by capillary area. Interestingly, the remaining increase in capillary area fraction 
over that in the sham-operated hind-limb was not uniformly distributed throughout the muscle. In 
two of the three areas analysed, angiogenesis occurred but was depressed in the Txnrd2ECKO mice 
compared to Txnrd2ECWT mice. In the third area, no increase from the basal capillary area fraction as 
measured in the sham-operated limb was observed in either experimental group. We suspect that 
anoxia rather than hypoxia may have occurred in this area, either due to a steal effect of the 
vasculature in the other areas or of a higher local O2 consumption due to the muscle fibre type. 
Indeed, H&E staining revealed tissue necrosis in the third analysed area of the gastrocnemius muscle 
of both Txnrd2ECWT and Txnrd2ECKO mice. 
The acute occlusion of the femoral artery leads to an immediate and substantial decrease in 
perfusion of the calf muscle. Consequently, the lack of oxygen delivery results in tissue hypoxia which 
can be a considerable stimulus for angiogenic vessel growth. After all, angiogenesis is thought to 
improve perfusion conditions in the affected area and, consequently, of oxygen delivery. It is thus 
plausible that hypoxia and the subsequent activation of hypoxic signalling cascades function as major 
stimuli for capillary sprouting. Major participants in the hypoxic stimulation of angiogenesis are the 
hypoxia inducible transcription factor HIF-1α, its regulators PHD2 and FIH, and the products of HIF-1α 
target genes such as VEGF. This seemingly unambiguous link between hypoxia and angiogenesis, 
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however, is confounded by the regulation of the corresponding signalling cascades, and especially 
the involvement of ROS in the regulation of HIF-1α.  
For long it was accepted that hypoxia but not anoxia leads to an increase in ROS which is required for 
the stabilisation of HIF-1α. A series of publications in 2005 as well as a recent follow-up study 
suggested that radicals from complex III of the ETC are necessary for the induction of hypoxic 
signalling via the stabilisation of HIF-1α 85, 153-155. Furthermore, one of these studies as well as a recent 
report implicated especially H2O2 in the process of HIF-1α stabilisation either by exogenous 
administration of H2O2 or by increasing its scavenging via the administration of exogenous  
catalase 86, 155. In these reports, ROS are commonly suggested to impair the hydroxylation of proline 
residues of HIF-1α by PHD2, most likely via the oxidation of the essential co-factor for PHD2, the non-
heme Fe2+. 
Recently, however, this axiom of hypoxia-dependent ROS production has begun to falter. Oxygen is, 
by definition, required for the production of ROS. To increase the production of oxygen radicals while 
the essential ingredient, oxygen, is scarce appears contradictory. In line with this presumption, the 
mitochondrial production of H2O2 has been reported to be positively correlated to cellular oxygen 
levels, implying that a decrease in oxygen, as is the case during hypoxia, will actually decrease H2O2 
production 157. Accordingly and in contrast to the above reports, mitochondrial production of H2O2 
has also been reported to decrease during hypoxia in cardiac myocytes from guinea pigs and in 
mitochondria isolated from rat hepatocytes 87, 158. Furthermore, as early as 1996, the application of 
exogenous H2O2 was shown to decrease HIF-1α accumulation during experimental hypoxia  
in vitro 159. Possibly, as proposed in a recent review, an actual hypoxia-induced production and 
release of ROS indeed increases HIF-1α levels which itself then acts upon the mitochondria in the 
fashion of a negative feedback loop to curtail ROS production 160. This, however, does not exclude 
the possibility of reactive oxygen species production by other, non-mitochondrial systems. In line 
with the suggestion of a negative feedback loop curtailing mitochondrial ROS production, 
mitochondrial-derived ROS in response to acute hypoxia have been suggested to elicit an even 
greater production of ROS by NAD(P)H oxidase via MEK/ERK signalling pathways 161. Furthermore, 
hypoxia can induce the activation of Xanthine Dehydrogenase and Xanthine Oxidase in a 
mitochondria-independent fashion, also resulting in the production of ROS 162-166. It thus appears 
crucial to consider the timing when attempting to measure ROS levels in response to hypoxia. 
Finally, a more critical review on this topic concluded that to date no consensus on the precise 
response of mitochondria to hypoxia in regard to ROS production can be reached and that, possibly, 
one should abandon the theory that mitochondria regulate HIF-1α stabilisation via the production of 
ROS and rather address whether mitochondria as a major consumer of oxygen can regulate HIF-1α 
stability by altering cellular oxygen concentrations 167.  
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Considering that our in vitro results revealed elevated basal levels of ROS and, as indicated by the 
decrease in ΔΨm, an impairment of mitochondrial function in cells lacking Txnrd2, it is somewhat 
irrelevant whether hypoxia increases or decreases mitochondrial ROS production and how this 
affects HIF-1α stability. Rather, the question must be how the elevated basal ROS levels can impair 
the cellular response to hypoxia and handle HIF-1α stabilisation. Or, if a negative-feedback loop from 
HIF-1α to the mitochondria to decrease the production of ROS indeed exists, whether the 
Txnrd2/Txn2/Prx3 axis, which is dysfunctional in the Txnrd2-deficient eEPCs (and in the endothelium 
of Txnrd2ECKO mice) employed in this study, is normally required to suppress a further increase of 
mitochondrial H2O2. A previous study by our group addressed this issue using Mouse Embryonic 
Fibroblasts lacking Txnrd2 and transformed with the pro-oncogenes c-myc and Ha-ras. Implanted 
subcutaneously into the flank of normal mice, tumour angiogenesis was significantly impaired 
relative to corresponding cells positive for Txnrd2, and this was accompanied by decreased protein 
levels of HIF-1α and VEGF 37. In line, an attenuated tube formation capacity of Txnrd2-/- eEPCs was 
also demonstrated in that study. Hence, these results and the findings on impaired angiogenesis 
from the present study suggest that elevated basal levels of ROS indeed impair hypoxic signalling, 
including HIF-1α, in vivo.  
The observation of significantly higher protein levels of PHD2 in Txnrd2-/- eEPCs may also indicate the 
contribution of PHD2 to the impairment of angiogenesis in Txnrd2ECKO mice. Unfortunately, 
information on the effects of increased PHD2 protein levels in vascular remodelling processes is 
scarce. However, the opposite – low levels of PHD2 protein – has been investigated more thoroughly, 
especially in the context of tumour angiogenesis but also in non-carcinogenic vessel maturation. 
Inducible, ubiquitous deletion of PHD2 in adult mice resulted in excessive angiogenesis, in which the 
vessels were perfusable and successfully recruited VSMC, suggesting that PHD2 is a negative 
regulator of vascular growth 168. Using mice haplodeficient for PHD2, it was suggested that this 
protein can also affect the quality of newly formed tumour vessels 169. In this study, ECs (and other 
cells) themselves expressed lower protein levels of PHD2 and while growth of implanted, PHD2-
expressing tumours itself was not changed in PHD2+/- mice, perfusion was significantly augmented 
and metastasis reduced, indicating that the reduction in PHD2 expression favoured the maturation of 
tumour vessels 169. In the aforementioned studies, however, the authors did not consider the 
assessment of HIF-1α signalling in response to reduced PHD2 protein expression. Chan and 
colleagues, on the other hand, showed not only that various cancer cell lines and tumours express 
lower levels of PHD2 and display an increase in the number of blood vessels, but also that silencing of 
PHD2 with short hairpin RNA (shRNA) further reduced PHD2 protein expression in tumours and 
resulted in even greater angiogenesis 170. Most importantly, however, they demonstrated that the 
increase in angiogenesis remained even when both PHD2 and HIF-1α were silenced with shRNA in 
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tumour cells, indicating that PHD2 indeed exerts HIF-1α-independent effects on angiogenesis 170. In 
support, Takeda and Fong showed that elevated PHD2 expression impaired EC proliferation  
in vitro 171. By employing a recombinant PHD2 mutant lacking hydroxylase activity they also 
supported an inhibitory, HIF-1α-independent effect of PHD2 itself on EC proliferation 171. Considering 
that to date the majority of publications focus on investigating the effect of reduced PHD2 expression 
on angiogenesis, it is intriguing to report that the Txnrd2-/- eEPCs, and thus possibly also the 
endothelium of Txnrd2ECKO mice employed in this study, express elevated PHD2 protein levels despite 
the exact reason for this observation remaining elusive in this study. In light of the published 
literature, however, an elevation of PHD2 protein levels could serve as the major mechanism 
responsible for the impairment of the angiogenic response in the hypoxic calf muscle after femoral 
artery ligation by suppressing the proliferative capacity of the ECs.   
In addition to the involvement of ROS, PHD2 and/or HIF-1α in the response to hypoxia, Txnrd2 or any 
of its substrates could potentially be more directly involved in the regulation of hypoxic signalling. 
Interestingly, the protein and mRNA levels of the cytoplasmic equivalent to Txnrd2, Txnrd1, are 
reduced during hypoxia, independently of HIF-1α stability in transformed fibroblasts and in a mouse 
breast cancer cell line 172. Furthermore, hypoxia also caused a reduction in Txnrd1 activity in these 
cells which suggests further post-translational modifications of the enzyme. While the authors of this 
study observed a general increase in ROS levels in response to hypoxia, this increase was attenuated 
in cells lacking Txnrd1, suggesting that ROS are indeed required for hypoxic signalling – however, 
independent of HIF-1α signalling. Furthermore, these findings suggest that not an increased 
formation of ROS occurs in response to hypoxia but rather a decreased detoxification of H2O2. 
Possibly, so the authors speculated, the downregulation of Txnrd1 may also serve in the modification 
of transcription factors that are substrates for this enzyme, such as AP-1 or NFκB. However, this 
would inevitably also activate gene transcription of genes potentially counterproductive for 
angiogenesis such as ASK1, leading to pro-apoptotic signalling 89. Obviously, the role of ROS 
production, removal, HIF stability and PHD activity still remains elusive albeit the substantial increase 
of efforts to elucidate the exact mechanisms. While the above excursion into possible pathways 
cannot be narrowed down to a decisive role of ROS in hypoxic angiogenic signalling, the findings on 
HIF-independent Txnrd1 sensitivity to hypoxia and the impact of Txnrd2 deletion on PHD2 expression 
and especially angiogenesis in both tumour growth and in the present study will provide alternative 
avenues that should be considered in the quest to gain a comprehensive and integrated 
understanding of these complex processes. 
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4.3.2 Arteriogenesis 
As described above, hind-limb ischemia, induced by the surgical occlusion of the femoral artery, 
leads to both arteriogenesis and angiogenesis. Seven days after the occlusion of the femoral artery, 
the vessels of the lower limbs were maximally dilated and perfusion fixed with paraformaldehyde 
prior to excision of the adductor of the ischemic and the sham-operated hind-limb. Subsequently, the 
muscles were embedded in paraffin and sections cut in a plane allowing the evaluation of the cross-
sectional area of the wall and lumen of the vessels. Following H&E staining of the sections, wall area 
of the same collateral arterioles was measured at the middle part of the thigh muscle and compared 
between the limbs (sham vs. occluded) and the genotype of the mice (Txnrd2ECWT vs. Txnrd2ECKO). As 
expected, occlusion of the femoral artery led to a significant increase in collateral arteriole wall area 
in the adductor muscle of the ischemic hind-limb regardless of the genotype. Importantly, this 
increase was significantly attenuated in Txnrd2ECKO mice compared to their Txnrd2-expressing 
counterparts, indicating that the arteriogenic response is also blunted in mice lacking EC Txnrd2. 
Using the data from the inner and outer circumference of the collateral arterioles, vessel wall 
thickness and lumen were calculated using standard circle formulas. Since these parameters were 
also employed for the assessment of wall area, analogous results were achieved: Wall thickness was 
increased in collateral arterioles in the occluded hind-limbs while in the mice lacking EC Txnrd2 this 
increase was significantly blunted. Likewise, the luminal diameter was significantly smaller in 
Txnrd2ECKO mice compared to the corresponding Txnrd2ECWT mice.  
Interestingly, both wall area and wall thickness but not the luminal diameter of the collateral 
arterioles were also significantly increased in Txnrd2ECKO mice in the sham hind-limb, indicating that 
these vessels were larger at baseline. In the case of the wall thickness of the arterioles in the 
occluded limb, where no significant difference between Txnrd2-expressing mice and those lacking 
Txnrd2 in the ECs was detected when comparing the raw data, this could indicate that an additional 
increase of wall thickness in the Txnrd2ECKO mice may not have been possible as a maximal size had 
been achieved. However, the fact that wall area and luminal diameter in the collaterals from the 
occluded hind-limbs of Txnrd2ECKO mice were both impaired, also without normalising the data, 
demonstrates that the capacity of the vessels to remodel in these mice is indeed decreased. 
The remodelling of the collateral arterioles is of substantial importance in this model; after all, 
hypoxia in the calf muscle will endure until adequate blood supply has been re-established via these 
upstream collaterals. Thus, a decrease in the arteriogenic capacity of the collateral vessels in the 
thigh muscle will ultimately also affect any potential positive effect on angiogenesis in the calf 
muscle. However, as discussed in the previous section, angiogenesis was attenuated in Txnrd2ECKO 
mice, further supporting a substantial impairment of the endothelium of these animals. 
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Regarding the interplay of arteriogenesis and angiogenesis and in contrast to the latter, the 
mechanism driving the remodelling of the collateral arterioles is not induced by hypoxia 48, 52. After 
all, the collateral vessels do transport blood, oxygen and nutrients to the thigh muscles. The exact 
stimuli responsible for the induction of collateral artery remodelling in this muscle remains a topic of 
considerable debate; however, the majority of publications propose that an increase in FSS in the 
collateral arterioles following the occlusion of the femoral artery serves as the inaugural signal 45, 53. 
While several authors discuss arteriogenesis in the context of it being a FSS-driven process, it is often 
ignored that an increase in FSS in the collateral circulation following the occlusion of a main artery 
has not been measured as such yet. Furthermore, an increase in FSS leads to rapid collateral 
vasodilatation after acute occlusion of the femoral artery, as was demonstrated more than four 
decades ago by Rosenthal and Guyton 173. And since vessel radius has a major impact on shear stress 
according to the formula , where Q represents flow velocity and η viscosity, a 
rapid flow-mediated vasodilatation would tend to return FSS to normal levels, thereby decreasing the 
impact of FSS as an – at least continuously – contributing stimulus 55, 71, 174-177. Nevertheless, that an 
increase in FSS can indeed induce collateral arteriole remodelling was elegantly demonstrated in two 
studies in which the hind-limb ischemia model employed here was extended by the creation of an 
arteriovenous shunt between the distal femoral artery stump and the femoral vein. This led to a 
substantial additional pressure drop across the length of the collateral arterioles and resulted in 
further arteriogenesis of the collateral arterioles above that observed in the ‘classical’ occlusion 
model 53, 71.  
If FSS is considered as an integral stimulus for the remodelling of the hind-limb collateral arterioles, 
focus must centre on the constitution of the endothelium as these are the only cells that can sense 
this force. Accordingly, functional integrity of ECs is required to translate this biomechanical force 
into biochemical signals for the underlying structures such as the VSMCs. Fluid shear stress sensing 
and transmission occurs in a decentralised fashion and involves signalling from the luminal surface 
(including the glycocalyx, G-protein coupled receptors, ion channels and tyrosine kinase receptors), 
from intracellular structures (such as the cytoskeleton, focal adhesion and integrin-linked kinases, 
various adaptor proteins and the nuclear membrane), and from abluminal connectors, (e.g. integrins 
and their respective extracellular matrix proteins) 44, 178, 179. An intact endothelium will integrate 
signals from these sources and translate changes in FSS to a biochemical signal, for example by 
increasing eNOS mRNA and/or activity, resulting in a sustained production and release of NO and 
subsequent relaxation of the underlying VSMCs 56, 180, 181. Furthermore, the levels of adhesion 
molecules such as ICAM-1 and VCAM-1 are altered during increased FSS as is the activity of a range 
of transcription factors such as AP-1 and NFκB as well as growth factors like bFGF and platelet-
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derived growth factor 60, 67-69, 182. Importantly, FSS has been reported to alter the oxidative capacity of 
ECs, resulting in increased levels of ROS, including H2O2, both in vitro and in vivo 
58, 59, 93, 94, 183. A recent 
study demonstrated that different flow characteristics elicit specific effects on both the activity of 
sources of ROS (e.g. increased ROS from NAD(P)H oxidase) as well as of antioxidants such as 
glutathione peroxidase and catalase (decreased detoxification) 184. The FSS-dependent reduction of 
catalase activity was shown to occur via decreased PKCδ activity, resulting in an accumulation of  
H2O2 
181. By increasing Akt signalling, the elevated levels of H2O2 indirectly led to the phosphorylation 
of eNOS at the activity-enhancing Ser1177, thereby also increasing NO production 181. Consequently, 
this and the possibility that one or more of the mechanosensors and –transmitters could potentially 
be modulated by ROS raises the question what occurs in response to increased FSS in dysfunctional 
ECs or those already struggling to curb oxidative stress at basal levels, such as the Txnrd2-deficient 
eEPCs or EC in the current study. 
The results obtained in vitro with eEPCs and MEFs demonstrate that the deletion of Txnrd2 results in 
a significant increase in basal ROS levels, an effect likely to also occur in the endothelial cells of the 
Txnrd2ECKO mice in vivo. It is therefore possible that these ECs are incapable of responding adequately 
to the haemodynamic alterations they are exposed to after occlusion of the femoral artery, especially 
when one considers that both FSS as well as stretch result in increases in ROS 93, 185. Excessive levels 
of ROS are implicated in numerous diseases affecting the vascular wall, such as hypertension and 
atherosclerosis as well as in vascular complications associated with increasing age. For example, the 
increase in luminal diameter of remodelling collateral arterioles in young rats is attenuated in aged 
rats; an effect that could be reversed by administration of antioxidants 101. Furthermore, increasing 
age and the related rise in ROS impairs the activation of eNOS and thus FSS-induced  
vasodilatation 186. The impairment in luminal expansion and FSS-induced arterial remodelling in aged 
rats has been suggested to be due to a decreased sensitivity of these ECs to subtle changes in FSS 102. 
Furthermore, impaired vasodilatation due to elevated levels of ROS has also been described 
employing Txnrd1 inhibitors 35.  
However, we could not detect an impairment in EC sensitivity to changes FSS in isolated collateral 
arterioles in this study. Whether this is due to experimental restrictions or a true result remains 
elusive and is under current investigation. Likewise we cannot deduce from our results whether the 
translation from the biomechanical stimulus of FSS to a biochemical signal relevant for vasodilatation 
and/or vascular wall remodelling is potentially derailed. Possibly, eNOS is uncoupled or NO 
scavenged rapidly by excess O2
-•, leading to the production of ONOO-. Yet, we have been unable to 
detect an increase in protein tyrosine nitration, an indirect evaluation of ONOO- formation, neither in 
lysates from eEPCs or MEFs either untreated or stimulated with the NO donor SNAP, nor in lysates 
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from remodelled collateral arterioles of Txnrd2ECKO mice. Possibly, though, results from lysates from 
the collaterals are confounded by other, Txnrd2-expressing, cells such as VSMCs or pericytes. 
In continuation of the aforementioned association of thioredoxin systems and NO, another role for 
NO, the nitration of free cysteine thiol-groups in proteins, could possibly also contribute to the 
decrease in arteriogenesis observed in Txnrd2ECKO mice 187. Indeed, upon exposure to FSS, S-
nitrosylation of free SH-groups of proteins, including Txn1, has been reported to increase 188. Like the 
phosphorylation of specific residues as a method for post-transcriptional protein regulation,  
S-nitrosylation can alter the activity of proteins 189. Similarly to the reduction of oxidised proteins by 
Txns, the vicinal dithiols of these disulfide oxidoreductases also enable them to function as 
denitrosylators 189. In support, Txnrd1 and Txnrd2 have indeed been described to participate in the 
denitrosylation of proteins. In the mitochondria, for example, the presence and activity of Txnrd2 is 
essential for the activation of caspase-3 which is usually neutralised by constitutive S-nitrosylation to 
prevent the induction of apoptosis 189. Without Txnrd2, caspase-3 cannot be activated, thereby 
preventing caspase-3-induced apoptosis. Since arteriogenesis requires a concerted activation and 
deactivation of specific proteins involved in processes such as signalling as well as controlled 
proliferation and intracellular communication, it would be possible that a lack of Txnrd2 could 
potentially result in a continuous S-nitrosylation and therefore deregulation of proteins critically 
involved in the process of arteriogenic vascular growth. 
Another reason for the reduced arteriogenesis in Txnrd2ECKO mice suggests itself from the dissipation 
of ΔΨm we observed in eEPCs. Since the ΔΨm is required for the movement of ions, including 
calcium, through the mitochondrial membranes, mitochondrial calcium handling may be impaired. 
Correct calcium signalling is required for the initiation of FSS-dependent eNOS activation in the 
endothelium 110. Impaired EC mitochondrial calcium handling in the Txnrd2-deficient ECs could 
therefore possibly lead to a delayed activation of eNOS and thus NO production and consequent 
vasodilatation. Furthermore, the release of Ca2+ from the mitochondria to the ER to replenish its 
stores via the Ca2+/Na+ exchanger is susceptible to modification by mitochondrial H2O2, an effect that 
could also blunt NO-dependent processes in the endothelium of Txnrd2ECKO mice 111, 112. 
In addition to the effects the deletion of Txnrd2 elicits in the endothelium, effects beyond these cells 
could possibly contribute to the blunted arteriogenic response in Txnrd2ECKO mice. Especially H2O2, 
the oxidant normally detoxified by the thioredoxin systems, can move across certain membranes and 
H2O2 derived from endothelia has been shown to affect the underlying VSMCs where it influences 
arteriogenesis by the induction of PLGF production 94, 190.  
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Thus, the critical role of the endothelium in mediating FSS-dependent vasodilation implies that an 
impairment of these cells will ultimately impact on arteriogenesis. Since the only cell type affected 
the Txnrd2ECKO mice is the endothelium, it is plausible that any of the mechanisms discussed above 
could be defective, resulting in a blunted arteriogenic response.  
While we and others have shown that Txnrd2 deletion increases ROS levels and that this is most 
likely due to an impairment of the Txnrd2/Txn2/Prx3 axis, the lack of Txnrd2 itself or the resulting 
impaired function of Txn2 as well as other, possibly yet unidentified substrates for Txnrd2, may 
contribute to the compromised arteriogenic response to hind-limb ischemia observed in this  
study 37, 39, 116, 191.  
Finally, evidence for the importance of the thioredoxin system in vascular homeostasis in the context 
of human disease can be deduced from the findings that hypertensive patients with impaired EC-
dependent vasodilatation present significantly reduced plasma levels of selenium compared to other 
hypertensive patients with an intact EC-dependent vasodilatory response 192. This finding is intriguing 
as selenium is essential in the maintenance of selenoproteins such as Txnrd2 and depletion of this 
trace element can lead to a loss of Txnrd2 activity 193.  
4.3.3 Endoplasmic Reticulum Stress 
Since mitochondria are in close proximity to the ER we also investigated the possibility of an 
impairment of ER function in cells lacking Txnrd2 194, 195. Indeed, mitochondria are tethered to the ER 
via mitofusin-2, thereby forming mitochondria-associated-membranes which are patches of ER 
membranes attached to the mitochondria 196. These microdomains have been shown to comprise up 
to 5-20% of total mitochondrial network surface area, suggesting that mitochondrial and ER 
functions are closely linked 194, 197. The main reason for the close proximity of these two organelles 
appears to be their involvement in Ca2+ signalling. The ER, in addition to the sarcoplasmic reticulum 
in myocytes, represents one of the major cellular stores of Ca2+ 198-200. But the mitochondria can also 
take up Ca2+ and this ability implies the mitochondria as buffers of cytosolic Ca2+ levels 194, 195. 
Furthermore, the close apposition of the mitochondria and the ER enables the mitochondria to sense 
the initiation of ER-dependent Ca2+ signalling directly at the points of origin, the ER Ca2+ channels; 
information which can be harvested directly, e.g. to alter the organelle’s metabolism 194, 195. Uptake 
of ions into the mitochondria, however, is dependent on their electrochemical gradient and requires 
the presence of a sufficient ΔΨm – which is, as discussed above, negatively affected by Txnrd2 
deletion in eEPCs investigated in this study 110. In addition to the mitochondria participating in Ca2+ 
signalling and in the regulation of cytosolic levels, these organelles are also required for the 
replenishment of ER Ca2+ stores via the Na+/Ca2+ exchanger, a channel that is sensitive to regulation 
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by H2O2 
112. Since Txnrd2 ablation leads to significantly increased levels of ROS, most likely via an 
increase in H2O2, we suspected that cells lacking Txnrd2 may also present impairments of the ER.  
The lumen of the ER represents a unique oxidising environment, allowing the efficient formation of 
disulfide bonds in the folding of proteins mainly designated for secretion and membrane-bound 
expression 197, 198, 201, 202. The redox reaction of disulfide bond formation is catalysed mainly by PDI, a 
protein that was predicted and then also confirmed more than two decades ago to exhibit sequence 
similarity to Txn and therefore may also be a substrate for Txnrds 24, 203, 204. Similarly, two ER-resident, 
PDI-like proteins, now identified as P5 and ERp72, as well as other members of the expanding family 
of PDIs, also possess structural similarities with Txns and their activity could possibly also be 
regulated by Txnrds 25, 205. The presence of Txnrd2 splice variants in cellular areas other than the 
mitochondria could thus potentially act as reductases for such PDIs 206. Considering that the ER 
contributes to such vital cellular processes as calcium storage, release and signalling as well as the 
three-dimensional folding of proteins, it is evident that ER homeostasis must be maintained. The 
observation that Txnrd2 ablation leads to significantly increased levels of ROS, most likely via an 
increase in H2O2, and the dissipation of ΔΨm, as well as the possibility of a direct involvement of the 
mitochondrial thioredoxin system in ER function, we speculated that the function of the ER may also 
be compromised in Txnrd2 knockout cells. 
To investigate this, we analysed markers characteristic of ER stress. Derailed ER function, elicited 
either by insufficient Ca2+ levels or by the accumulation of misfolded proteins in the ER lumen, can 
initiate the unfolded protein response (UPR) 202, 207. The UPR is initiated by the release of the ER-
resident proteins PERK, IRE1α and ATF6 to re-establish ER homeostasis or, if this fails, to proceed to 
apoptotic cell death 207. The transcriptional increase of UPR genes, including BiP (also known as 78 
kDa glucose-regulated protein) and PDI, the reduction of cellular protein synthesis to decrease ER 
work load, as well as augmented ER-associated protein degradation are all aimed at re-establishing 
ER homeostasis 201, 202, 207. BiP is considered the major regulator of the UPR and acts in a positive 
feedback manner: normally, this chaperone is bound to the transducers of the UPR listed above from 
where it observes the correct folding of proteins. In the case of excessive protein misfolding, e.g. by 
ineffective PDI, BiP binds to incorrectly folded proteins to inhibit their release from the ER and 
accordingly liberates PERK, IRE1α and ATF6 which can then initiate UPR signalling 207. The resulting 
increase in BiP and PDI translation is then constructive to rectify incorrect disulfide bonds and 
prevent the release of misfolded proteins 201, 207. The activity of many ER proteins, including BiP, is 
critically dependent on the rich levels of Ca2+ normally present in the ER lumen 202. In order to 
maintain the Ca2+ levels within the ER in the µM to mM range (cf 100 nM in the cytosol), this 
organelle is equipped with Calcium-binding proteins such as calreticulin which can bind more than 
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50% of the total ER Ca2+ levels 199, 200, 208, 209. Thus, one could hypothesize that ineffective replenishing 
of ER Ca2+ stores in Txnrd2 knockout cells could potentially impair correct protein processing, a point 
that could be addressed in future studies.  
In the Txnrd2-deficient eEPCs and also in mouse embryonic fibroblasts protein levels of the ER stress 
markers BiP and PDI were indeed substantially upregulated. Whether this effect was due to the lack 
of Txnrd2 or due to oxidation of Txn2 remains elusive in this study. Apart from the effect the 
elevated ROS levels in Txnrd2 deficient cells may have on Ca2+ funnelling to the ER by mitochondrial-
expressed Ca2+ channels, ROS may also elicit ER stress by inactivating ER-resident Ca2+ channels and 
protein folding enzymes 197. Additionally, ROS-elicited ER stress may initiate a vicious cycle as 
deregulated oxidative protein folding itself also increase ROS 197, 203. Finally, increases in H2O2, as 
occurs in the response to changes in FSS or during hypoxia in vivo, lead to the transcription of 
numerous genes and consequently also production of proteins requiring correct assembly in the ER 
of ECs 210. Thus, the presence of an impaired ER as the elevated levels of BiP and PDI in Txnrd2-
deficient cells imply, could possibly advance the already detrimental effects observed here. 
In this study we could demonstrate that a lack of Txnrd2 not only leads to elevated levels of ROS and 
a loss of ΔΨm but is also associated with ER stress. ER stress could be both the consequence of 
Txnrd2 deficiency and could result in the incorrect folding of mediator proteins required for vascular 
remodelling, as well as a contributing and amplifying factor to the mitochondrial defect, e.g. by 
interfering with calcium homeostasis and signalling. 
Considering the plethora of effects ER stress can elicit, especially when unresolved, it is not surprising 
that the UPR is associated with numerous pathological conditions including obesity, diabetes, viral 
infections, neurodegenerative disorders, inflammation, and cardiovascular disorders 202. The 
manifestations of thrombi in blood vessels and the development of atherosclerosis have also been 
reported to occur increasingly when ER stress is present.  
4.3.4 Thrombus formation, atherosclerosis and future prospects 
We were intrigued to discover thrombi in the collateral arterioles of both the occluded and the 
sham-operated hind-limb while assessing the remodelling of the collateral vessels in the thigh 
muscles of Txnrd2ECKO mice following femoral artery occlusion. Especially in light of the in vitro 
findings on increased ROS levels and ER stress in eEPCs, we speculated whether these factors may 
also be associated in the formation of thrombi. Indeed, PDI is implicated in the activation of tissue 
factor, a protein expressed, amongst others, on the surface of ECs where it can increase the 
proteolytic activity of a number of factors involved in the coagulation cascade of fibrin and thrombus 
formation 211. PDI, while normally contained in the ER, may be released from ECs where it 
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participates in the thiol-dependent regulation of tissue factor by the formation of disulfide bonds of 
key cysteine residues in its sequence, thereby rendering it procoagulant 122, 211, 212. Indeed, recent 
studies have suggested that tissue factor activation by EC-released PDI is critical for the initiation of 
thrombus formation as PDI is detected prior to the onset of platelet and fibrin accumulation and 
inhibitors of PDI also inhibit the formation of fibrin at sites of vascular injury 122, 211, 212. Whether this 
observation of white thrombi in Txnrd2ECKO mice serves as an indication for aberrant activation of 
blood coagulation due to increased ER stress will be the focus of future studies as it is beyond the 
scope of this project.  
Additionally, in the femoral artery of Txnrd2ECKO mice we observed sub-intimal infiltrations in the 
vascular wall, leading us to speculate that these mice may be more susceptible to atherosclerosis 
compared to their wildtype counterparts. In atherosclerotic plaques, increased markers of ER stress 
have been reported in macrophages and VSMCs but also ECs 213. The increase in ER stress markers in 
ECs occurs mainly at atherosusceptible regions in vivo, as has been exemplified by the expression of 
BiP and the UPR-associated proteins IRE1α and ATF6 at the inner aortic arch, the intercostal branch 
points of the thoracic aorta and the renal branches 214, 215. While increased ER stress at these sites can 
augment the aptitude of the ER to fold proteins and thus serve as an adaptive and protective 
response by counteracting the pathological aggregation of misfolded proteins, the oxidative folding 
of proteins also generates ROS which, especially when increased ROS levels already exist, can cause 
inflammation. Inflammation, in turn is critically involved in the initiation and progression of 
atherosclerotic lesions 214. Furthermore, chronic exposure to additional risk factors, including 
elevated levels of ROS, can tip the balance of adaptive ER stress to a terminal UPR, resulting in 
apoptosis and atherosusceptible EC phenotypes 213, 214.  
While further evidence is required to support the suggestion of an increased susceptibility of Txnrd2-
deficient ECs to the development of atherosclerosis, our results on impaired vascular remodelling, 
the presence of thrombi and the measurements of mitochondrial impairment, increased ROS and ER 
stress, and the numerous reports in the literature which implicate exactly these parameters in the 
formation of atherosclerotic lesions warrant further investigation of the mitochondrial thioredoxin 
system and other thiol reducing enzymes in the initiation and progression of  
atherosclerosis 105, 109, 213, 216-218. 
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5 Conclusion 
The present study demonstrates that the mitochondrial enzyme Thioredoxin Reductase 2 (Txnrd2) 
can considerably affect endothelial cell (EC) function. The lack of this enzyme leads to elevated basal 
levels of reactive oxygen species (ROS), resulting in the depolarisation of the mitochondrial 
membrane and endoplasmic reticulum (ER) stress. These cellular effects impair the ability of the 
vascular system to adapt to severe flow reduction induced by the ligation of the femoral artery. The 
deficit in angiogenesis in the hypoxic calf muscle is likely due to enhanced HIF-1α degradation via 
elevated levels of PHD2 which itself is regulated by ROS. While Txnrd2 deletion also attenuated 
arteriogenesis, we could not detect a lack of endothelial sensitivity to shear stress or an impairment 
of NO availability, both requirements for the remodelling of collateral arterioles and typically 
affected by ROS. The precise mechanism, however, remained unclear. Besides these effects on 
vascular remodelling, an incidental observation also indicated that Txnrd2 deletion may also promote 
thrombus formation, possibly due to the release of thrombogenic ER stress proteins. 
This project adds insight into the role of the mitochondrial thioredoxin system in the maintenance of 
endothelial integrity and extends the available knowledge on the participation of EC mitochondria 
and ROS derived thereof in vascular remodelling. Granting that this investigation only scratched the 
surface of the importance of Txnrd2 in mitochondrial and EC health, it demonstrates that further 
research into this field is indeed warranted. 
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6 Summary 
In the mitochondria, numerous antioxidant systems act in concert to prevent the toxic accumulation 
of reactive oxygen species and resulting oxidative stress. The mitochondrial thioredoxin system, 
consisting of peroxiredoxin 3, Thioredoxin 2 and Thioredoxin Reductase 2 are critically involved in the 
detoxification of hydrogen peroxide in order to maintain cellular redox homeostasis.  
Previous studies by our and other laboratories have demonstrated that an impairment of the 
mitochondrial thioredoxin system and recently, and also more specifically, the ablation of the 
mitochondrial Thioredoxin Reductase results in increased levels of ROS and affects cellular 
proliferation rates. Furthermore, studies in whole organisms have implicated the mitochondrial 
thioredoxin system in embryonic development, tumour growth, and heart function. While these 
findings critically contribute to solving the puzzle of the precise role of Thioredoxin Reductase 2, 
many pieces remain to be put together.  
In this study we aimed to add specific information to the understanding of Thioredoxin Reductase 2 
function in endothelial cells with respect to vascular remodelling processes. We chose to investigate 
this oxidoreductase in endothelial cells in vivo as their mitochondrial function differs from other cells 
which largely rely on aerobic glycolysis to meet their energy demands. The fact that endothelial cells 
generate ATP mainly via anaerobic glycolysis implies that the electron transport chain in the 
mitochondria of these cells may participate more in cellular signalling processes rather than in energy 
production. Accordingly, this study aimed to also investigate the involvement of Thioredoxin 
Reductase 2 in signalling processes and the regulation of angiogenic/arteriogenic endothelial cell 
function.  
We could show that the deletion of mitochondrial Thioredoxin Reductase leads to an increase in the 
levels of reactive oxygen species in embryonic endothelial progenitor cells which were used in the 
course of this study as sufficiently available substitutes for endothelial cells. Furthermore, these cells 
presented a partial dissipation of the mitochondrial membrane potential which is indicative of 
impending mitochondrial dysfunction. Since the mitochondria and the endoplasmic reticulum are 
closely associated both spatially and in terms of their function, we also revealed that deletion of 
Thioredoxin Reductase 2 in these cells results in endoplasmic reticulum stress. 
With the availability of a novel mouse model in which the deletion of Thioredoxin Reductase 2 can be 
induced specifically and exclusively in the endothelium we also investigated the role of this enzyme 
in vivo. Occlusion of the femoral artery in these mice exposed an impairment of the vascular 
remodelling responses in the collateral arterioles of the thigh which normally exhibit substantial 
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growth in order to form natural bypasses to re-establish blood perfusion to areas downstream of the 
femoral artery (arteriogenesis). Laser Doppler imaging revealed impaired reperfusion which mirrored 
the blunted increase in collateral arteriole wall area, wall thickness, and of the expansion of luminal 
diameter. Furthermore, in comparison to mice expressing Thioredoxin Reductase 2, the sprouting of 
capillaries (angiogenesis) in the hypoxic calf muscle was significantly impaired, possibly via increased 
PHD2 protein expression in the endothelium. Together with the in vitro results, these findings 
strongly suggest an important involvement of endothelial cell Thioredoxin Reductase 2, its substrates 
and the mitochondria in vascular remodelling. 
Interestingly, while assessing the impact of Thioredoxin Reductase 2 deletion on endothelium-
dependent vascular remodelling, we observed the presence of thrombi in some collateral arterioles 
in both the occluded limb as well as in the sham-operated limb. Furthermore, sub-intimal infiltrations 
in the wall of the femoral artery in endothelial cell Thioredoxin Reductase 2-defienct mice drew our 
attention to the possible involvement of this enzyme system in the susceptibility toward thrombosis 
and atherosclerosis, possibly via endoplasmic reticulum stress. This further supports our conclusion 
that the mitochondrial Thioredoxin Reductase plays an important role in vascular homeostasis.  
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7 Zusammenfassung 
Als Nebenprodukt der Atmungskette entstehen in den Mitochondrien zahlreiche reaktive 
Sauerstoffspezies (ROS). Um deren toxische Akkumulation zu verhindern und die mitochondriale 
Redox-Homöostase aufrechtzuerhalten, verfügen Mitochondrien über ein umfangreiches Netzwerk 
an antioxidativen Schutzsystemen. Eines dieser mitochondrial lokalisierten antioxidativen 
Schutzsysteme ist das  Thioredoxin-System, bestehend aus Peroxiredoxin 3, Thioredoxin 2 und 
Thioredoxin Reduktase 2, welches vor allem Wasserstoffperoxid entgiftet. 
Bisherige Studien zeigten, dass eine Beeinträchtigung des mitochondrialen Thioredoxin Systems und 
speziell die Ablation der mitochondrialen Thioredoxin Reduktase, zu einer Akkumulation von ROS 
führt und hierdurch die zelluläre Proliferation beeinflusst wird. Darüber hinaus zeigt ein genetischer 
knockout der mitochondrialen Thioredoxin Reduktase im Mausmodell Störungen in der 
Embryonalentwicklung, im Tumorwachstum als auch in der Herzfunktion. Während diese Ergebnisse 
bereits einen wesentlichen Beitrag zu der Entschlüsselung der genauen Bedeutung der Thioredoxin 
Reduktase 2 leisten konnten, stehen weiterhin Antworten auf zahlreiche Fragen aus. 
Ziel dieser Studie war es, die Funktion der Thioredoxin Reduktase 2 speziell in Endothelzellen 
hinsichtlich vaskulärer Homöostase sowie vaskulärer Umbauprozesse wie Angiogenese und 
Arteriogenese zu analysieren. Endothelzellen unterscheiden sich von vielen anderen Körperzellen 
dadurch, dass sie ihren Energiebedarf weitgehend durch Glykolyse und nicht über oxidative 
Phosphorylierung decken. Diese Tatsache deutet an, dass die mitochondriale Atmungskette dieser 
Zellen mehr an Prozessen innerhalb zellulärer Signalwege beteiligt sein könnte als an der 
Energieerzeugung. Dementsprechend soll diese Studie auch die Beteiligung von Thioredoxin 
Reduktase 2 in Signalprozessen und an der Regulation der Endothelzellfunktion in der Angiogenese 
und Arteriogenese untersuchen. 
Wir konnten zeigen, dass die Deletion der mitochondrialen Thioredoxin Reduktase zu einem 
Konzentrationsanstieg der ROS in embryonalen endothelialen Vorläuferzellen führt, die im Rahmen 
dieser Studie als Ersatz für adulte Endothelzellen verwendet wurden. Außerdem konnten wir in 
diesen Zellen eine partielle Dissipation des mitochondrialen Membranpotentials nachweisen, 
welches Indikativ für eine drohende mitochondriale Dysfunktion ist. Da die Mitochondrien und das 
Endoplasmatische Retikulum sowohl räumlich als auch im Hinblick auf ihre Funktion eng verbunden 
sind, stellten wir auch fest, dass die Deletion der Thioredoxin Reduktase 2 in diesen Zellen zu einer 
Stressantwort des Endoplasmatischen Retikulums führt. 
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Mittels eines Mausmodells, in dem die Deletion der Thioredoxin Reduktase 2 spezifisch und 
ausschließlich im adulten Endothel induziert werden kann, untersuchten wir auch die Rolle dieses 
Enzyms in vivo. Okklusion der Arteria femoralis in diesen Mäusen zeigte eine Beeinträchtigung der 
vaskulären Umbaureaktionen in den Kollateralarteriolen des Oberschenkels, welche normalerweise 
durch deutliches Wachstum natürliche Bypässe bilden, um die Durchblutung der nachgelagerten 
Bereiche wieder herzustellen (Arteriogenese). Mittels Laser Doppler konnte eine Beeinträchtigung 
der Reperfusion gezeigt werden, welche den abgeschwächten Zuwachs der Wandfläche und -dicke 
als auch die verringerte Expansion des Lumendurchmessers der Kollateralarteriolen wiederspiegelte. 
Darüber hinaus war die Neubildung von Kapillaren (Angiogenese) im hypoxischen Wadenmuskel 
dieser Mäuse im Vergleich zu Mäusen, die Thioredoxin Reduktase 2 im Endothel exprimieren, 
signifikant beeinträchtigt, möglicherweise durch eine erhöhte PHD2 Proteinexpression im Endothel. 
Zusammen mit den in vitro Ergebnissen deuten diese Befunde auf eine wesentliche Beteiligung der 
Thioredoxin Reduktase 2, seinen Substraten und den Mitochondrien in Endothelzellen an vaskulären 
Umbauprozessen hin. 
Interessanterweise beobachteten wir während der Beurteilung der Auswirkungen der Thioredoxin 
Reduktase 2 Deletion auf Endothel-abhängige Gefäßumbauprozesse das Vorhandensein von 
Thromben in einigen Kollateralarteriolen sowohl im okkludierten als auch im kontrolloperierten 
Hinterlauf dieser Mäuse. Subintimale Infiltrationen in der Wand der Arteria femoralis in Endothelzell-
Thioredoxin Reduktase 2- defizienten Mäusen richteten unser Augenmerk auf die mögliche 
Beteiligung dieses Enzymsystems an der Anfälligkeit für Thrombose und Arteriosklerose, 
möglicherweise über eine Stressantwort des Endoplasmatisches Retikulums. Dies unterstützt unsere 
Schlussfolgerung, dass die mitochondriale Thioredoxin Reduktase eine wichtige Rolle in der 
vaskulären Homöostase spielt. 
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9 Abbreviations 
Ang1 Angiopoietin 1 
ANOVA Analysis of variance 
AP-1 Activator protein 1 
ASK1 Apoptosis signal-regulating kinase 1 
ATP Adenosine triphosphate 
bFGF Basic fibroblast growth factor 
BH4 Tetrahydrobiopterin 
BiP Binding immunoglobulin Protein 
BSA Bovine serum albumin 
Ca2+ Calcium ion 
CCCP carbonyl cyanide 3-chlorophenylhydrazone 
cDNA Complementary DNA 
cGMP Cyclic guanosine monophosphate 
Cre Cre recombinase 
ΔΨm Mitochondrial membrane potential 
DMEM Dulbecco´s modified eagle´s medium 
DMSO Dimethyl sulfoxide 
DNA Desoxyribonucleic acid 
dNTP Desoxynucleoside triphosphate 
EC Endothelial cell 
EDHF Endothelium-derived hyperpolarising factor 
EDTA Ethylenediaminetetraacetic acid 
eEPC Embryonic endothelial progenitor cell 
eNOS Endothelial nitric oxide synthase 
ER Endoplasmic reticulum 
ETS Electron transport chain 
FAD Flavin adenine dinucleotide 
FCS Fetal calf serum 
Fe Iron 
FIH HIF asparaginyl hydroxylase Factor inhibiting HIF 
Flox LoxP-flanked 
FSC Forward scatter 
FSS Fluid shear stress 
H&E stain Hematoxylin and eosin stain 
H2O2 Hydrogen peroxide 
HIF-1α Hypoxia-inducible factor 1α 
HO• Hydroxyl radical 
HRP Horseradish peroxidase 
HUVEC Human umbilical vein endothelial cell 
Abbreviations 
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ICAM-1 Intercellular adhesion molecule-1 
JC-1 5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazolylcarbocyanine iodide 
LDI Laser Doppler Imaging 
MCP-1 Monocyte chemotactic protein-1 
MEF Mouse embryonic fibroblast 
mmHg Millimetres of mercury 
MMP Matrix metalloproteinase 
MOPS 3-morpholinopropanesulphonic acid 
mRNA Messenger ribonucleic acid 
Na Sodium 
NADPH Nicotinamide adenine dinucleotide phospate 
NFκB Nuclear factor кB 
NO Nitric oxide 
O2 Oxygen 
O2
-• Superoxide anion 
Occ Occluded 
ONOO- Peroxynitrite 
PBS Phosphate buffered saline 
PCR Polymerase Chain Reaction 
PDI Protein Disulfide Isomerase 
PHD2 prolyl hydroxylase 2 
PLGF Placenta growth factor 
Prx Peroxiredoxin  
pVHL von Hippel-Landau tumour suppressor protein 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
SD Standard deviation 
SDS Sodium dodecyl sulfate 
SDS-Page Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
Sec Selenocysteine 
SEM Standard error of the mean 
shRNA Short hairpin RNA 
siRNA Small interfering RNA 
SNAP Sodium nitroprusside 
SOD Superoxide dismutase 
SSC Side scatter 
TAE buffer Tris-acetic acid-EDTA buffer 
TBST Tris-buffered saline with Tween 
TE buffer Tris-EDTA buffer 
Abbreviations 
110 
 
TNF-α Tumour necrosis factor-α 
Txn Thioredoxin 
Txn1 (cytosolic) Thioredoxin 1 
Txn2 (mitochondrial) Thioredoxin 2 
TXNIP Thioredoxin-interacting protein 
Txnrd Thioredoxin reductase 
Txnrd1 (cytosolic) Thioredoxin reductase 2 
Txnrd2 (mitochondrial) Thioredoxin reductase 2 
Txnrd2ECKO mouse Mouse lacking Txnrd2 in the endothelium 
Txnrd2ECWT mouse Mouse expressing Txnrd2 in the endothelium 
UPR Unfolded protein response 
VCAM-1 Vascular cell adhesion molecule-1 
VEGF Vascular endothelial growth factor 
VSMC Vascular smooth muscle cell 
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